

1 **The assembly of neutrophil inflammasomes during COVID-19 is mediated by type I**  
2 **interferons**

3 **Luz E. Cabrera<sup>1,\*</sup>, Suvi T. Jokiranta<sup>2,3</sup>, Sanna Mäki<sup>1</sup>, Simo Miettinen<sup>1,4</sup>, Ravi Kant<sup>1,4,5</sup>,**  
4 **Lauri Kareinen<sup>1,4</sup>, Tarja Sironen<sup>1,4</sup>, Jukka-Pekka Pietilä<sup>6,7</sup>, Anu Kantele<sup>6,7</sup>, Eliisa**  
5 **Kekäläinen<sup>2,3,10</sup>, Hanna Lindgren<sup>11</sup>, Pirkko Mattila<sup>11</sup>, Anja Kipar<sup>4,8,9</sup>, Olli Vapalahti<sup>1,4,10</sup>**  
6 **and Tomas Strandin<sup>1</sup>**

7

8 <sup>1</sup>Viral Zoonosis Research Unit, Medicum, Department of Virology, University of Helsinki, Helsinki,  
9 Finland.

10 <sup>2</sup>Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland.

11 <sup>3</sup>Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki,  
12 Finland.

13 <sup>4</sup>Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland.

14 <sup>5</sup>Department of Tropical Parasitology, Institute of Maritime and Tropical Medicine, Medical  
15 University of Gdansk, 81-519 Gdynia, Poland.

16 <sup>6</sup>Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki,  
17 Finland.

18 <sup>7</sup>Meilahti Vaccine Research Center MeVac, Department of Infectious Diseases, Inflammation Center,  
19 Helsinki University Hospital and University of Helsinki, Helsinki, Finland.

20 <sup>8</sup>Laboratory for Animal Model Pathology, Institute of Veterinary Pathology, Vetsuisse Faculty,  
21 University of Zurich, 8057 Zurich, Switzerland.

22 <sup>9</sup>Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological  
23 Sciences, University of Liverpool, Liverpool L3 3RF, UK.

24 <sup>10</sup>Division of Virology and Immunology, HUSLAB Clinical Microbiology, HUS Diagnostic Center,  
25 Helsinki University Hospital, Helsinki, Finland.

26 <sup>11</sup>Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki,  
27 Finland.

28

29 **Abstract**

30 The severity of COVID-19 is linked to excessive inflammation. Neutrophils represent a  
31 critical arm of the innate immune response and are major mediators of inflammation, but  
32 their role in COVID-19 pathophysiology remains poorly understood. We conducted  
33 transcriptomic profiling of neutrophils obtained from patients with mild and severe COVID-  
34 19, as well as from SARS-CoV-2 infected mice, in comparison to non-infected healthy  
35 controls. In addition, we investigated the inflammasome formation potential in neutrophils  
36 from patients and mice upon SARS-CoV-2 infection. Transcriptomic analysis of  
37 polymorphonuclear cells (PMNs), consisting mainly of mature neutrophils, revealed a  
38 striking type I interferon (IFN-I) gene signature in severe COVID-19 patients, contrasting  
39 with mild COVID-19 and healthy controls. Notably, low-density granulocytes (LDGs) from  
40 severe COVID-19 patients exhibited an immature neutrophil phenotype and lacked this IFN-I  
41 signature. Moreover, PMNs from severe COVID-19 patients showed heightened nigericin-  
42 induced caspase1 activation, but reduced responsiveness to exogenous inflammasome  
43 priming. Furthermore, IFN-I emerged as a priming stimulus for neutrophil inflammasomes,  
44 which was confirmed in a COVID-19 mouse model. These findings underscore the crucial  
45 role of neutrophil inflammasomes in driving inflammation during severe COVID-19.  
46 Altogether, these findings open promising avenues for targeted therapeutic interventions to  
47 mitigate the pathological processes associated with the disease.

48

49 **Keywords:** inflammasome, neutrophils, COVID-19, type I interferon, inflammation, innate  
50 immunity.

## 51 **Introduction**

52

53 Severe COVID-19 is characterized by a dysregulated immune response with an excessive  
54 production of pro-inflammatory cytokines and chemokines. Type I interferons (IFN-I) are  
55 critical antiviral cytokines in the innate immune responses against viral infections, drawing  
56 particular attention amidst the COVID-19 pandemic (1–3). While the IFN-I response helps to  
57 limit virus replication (3), its prolonged and uncontrolled activation is detrimental to the  
58 overall health of the patient (4). As part of the pro-inflammatory response, neutrophils are  
59 rapidly recruited to the site of infection in response to SARS-CoV-2 infection (5, 6).  
60 Prominent neutrophil recruitment in severe COVID-19 is associated with an increased  
61 number of immature low-density granulocytes (LDGs) in the circulation (7–9). The increased  
62 production and subsequent early release of immature cells from the bone marrow occurs in  
63 response to emergency myelopoiesis (9). This process is initiated by the body to enable the  
64 recruitment of innate immune cells into the tissues and to replenish the depleted leukocyte  
65 pool, in an effort to combat viral infections including SARS-CoV-2 (10). However, the  
66 premature release of these cells could be associated with the increased degranulation and  
67 formation of neutrophil extracellular traps (NETs) reported during SARS-CoV-2 infection, to  
68 which LDGs have a higher propensity than polymorphonuclear cells (PMN) (5, 6, 11).

69

70 Neutrophils are involved in several aspects of inflammatory processes, including the release  
71 of reactive oxygen species (ROS) and other pro-inflammatory mediators such as Interleukin-  
72 6 (IL-6) and IL-8. In addition, recent reports on COVID-19 highlight that neutrophils could  
73 be a major source of inflammasome derived IL-1 $\beta$ , which has been implicated as a substantial  
74 contributor to COVID-19 pneumonia (12). Inflammasomes are intracellular multiprotein  
75 complexes involved in the inflammatory response. In the presence of a pathogen, antigen

76 recognition by the immune system triggers the assembly of the inflammasome, a step known  
77 as the first signal. This is followed by the recruitment of adaptor molecules that activate  
78 NOD-like receptor (NLR) family members and the binding of the apoptosis-associated speck-  
79 like protein (ASC), finally activating the inflammasome complex (13). The triggered  
80 assembly of this complex is known as the second signal. Studies have shown that SARS-  
81 CoV-2 infection induces significant inflammasome activation in circulating and lung-  
82 infiltrating myeloid cells, such as monocytes and neutrophils (14–17). However, while the  
83 precise mechanism by which inflammasomes are activated in monocytes/macrophages is well  
84 established, less is known about molecular mechanisms of inflammasome formation in  
85 neutrophils. Thus, this study investigates the inflammasome formation in neutrophils during  
86 COVID-19 in more detail, also focusing on the different developmental stages of these cells.  
87 In addition, a recently established COVID-19 mouse model served to further explore the role  
88 of IFN-I in neutrophil inflammasome assembly.

## 89 **Materials and methods**

### 90 **Patient population**

91 Adult clinical patients with confirmed COVID-19 (RT-PCR positive for SARS-CoV-2) at  
92 Helsinki University Hospital (HUU) (hospitalized: n = 34; outpatients: n = 8) were enrolled  
93 in the present study. Blood samples were collected during hospitalization for the severe  
94 COVID-19 group, and after confirmation of diagnosis for the mild COVID-19 outpatient  
95 group. Samples for RNA sequencing were collected in 2020 and representing infections by  
96 the original and early SARS-CoV-2 variants, whereas samples for *ex vivo* culture  
97 experiments were collected in 2021-2022 likely representing infections by omicron  
98 subvariants of SARS-CoV-2. As controls, healthy blood donors were included for RNA  
99 sequencing (n = 7, age  $57 \pm 7$ , male/female 3/4) and *ex vivo* culturing experiments (n = 9, age  
100  $38 \pm 14$ , male/female 4/5). The study was approved by the Ethics Committee of the Hospital  
101 District of Helsinki and Uusimaa (HUS/853/2020, HUS/1238/2020). All volunteers gave a  
102 written informed consent, in accordance with the Declaration of Helsinki. For clinical  
103 correlation analysis, severe COVID-19 patients were further categorized by severity based on  
104 their need for hospitalization and oxygen supplementation, as described previously (7). For  
105 each patient, medical history and clinical data were collected through retrospective patient  
106 record review and are presented for the severe COVID-19, hospitalized patients in Table 1  
107 and as previously described (7). Calprotectin was measured from serum (diluted 1:1000) by  
108 ELISA, according to the manufacturer's protocol (calprotectin/S100A8 DuoSet kit, R&D  
109 systems).

### 110 **Isolation of granulocytes from human blood**

111 Blood samples from COVID-19 patients and healthy controls (HC) were collected in EDTA  
112 vacutainer tubes and transported to the laboratory. Peripheral blood mononuclear cells  
113 (PBMCs) or polymorphonuclear cells (PMNs) were isolated from whole blood by density  
114 gradient centrifugation using either Ficoll-Paque Plus (GE Healthcare) or Polymorphprep  
115 (Axis-Shield) respectively, following standard procedures including the use of 2 mM EDTA  
116 in PBS and red blood cell lysis with ACK lysis buffer (Lonza by Thermo Fisher).  
117 Subsequently, isolation of CD66<sup>+</sup> granulocytes (low-density granulocytes, LDGs) from the  
118 PBMC fraction was performed using the CD66abce MicroBead Kit (Miltenyi Biotec,  
119 Germany) with an MS column, according to the manufacturer's instructions. Both the  
120 positively selected CD66<sup>+</sup> LDGs and the isolated PMNs were then washed and counted,  
121 using a TC20<sup>TM</sup> Automated Cell Counter (Bio-Rad Laboratories, Inc.) with trypan blue  
122 staining for dead cell exclusion. All described procedures in this section were done at room  
123 temperature. An aliquot of cells was lysed in Trizol reagent (Thermo Fisher Scientific, USA)  
124 and stored at -80°C for later extraction of total RNA and subsequent RNA sequencing  
125 (RNA-seq) analysis.

## 126 **Caspase1 activity**

127 Caspase1 activity was assessed in isolated cells after 2 h of culture (1 million cells/ml) using  
128 the caspase-Glo<sup>®</sup>1 inflammasome assay (Promega) according to the manufacturer's protocol,  
129 with 2.5 µM nigericin (Invivogen) treatment as the activator. The resulting luminescence was  
130 measured by a Hidex Sense microplate reader (Hidex).

## 131 **Soluble factor stimulation assays**

132 Isolated granulocytes from HC and COVID-19 patients were cultured at 2 million cells/ml in  
133 RPMI 1640 supplemented with 10% fetal bovine serum (R10) at 37°C. Cells were primed (1<sup>st</sup>  
134 signal) with either LPS (20 ng/ml, Sigma Aldrich) or IFN-I (combination of 2.7\*10<sup>4</sup> IU/ml

135 IFN- $\alpha$  and IFN- $\beta$ , Immunotools) for 4 h, followed by activation (2<sup>nd</sup> signal) by 2.5  $\mu$ M  
136 nigericin or monosodium urate crystals (MSU, 100  $\mu$ g/ml, Invivogen) for an additional 4 h.  
137 For the 24 h stimulation experiments, nigericin was added to the cultured cells, in the  
138 presence or absence of inflammasome inhibitors MCC995 (2  $\mu$ g/ml) and Ac-YVAD-FMK  
139 (20  $\mu$ g/ml, both from Invivogen). Cells were pelleted by centrifugation at 400 G for 5 min and  
140 stored in Trizol at  $-80^{\circ}\text{C}$  for later RNA extraction whereas supernatants were used to  
141 measure IL-1 $\beta$ , IL-18, myeloperoxidase (MPO) and IL-8 by ELISAs according to the  
142 manufacturer's protocols (DuoSet kits from R&D systems). LDH was measured in  
143 supernatants using Cyquant LDH cytotoxicity assay (ThermoFisher). HL-60 cells (ATCC  
144 #CCL-240) were activated similarly to neutrophils after a 5-day differentiation period  
145 induced by 1 % DMSO.

146

#### 147 **Virus propagation**

148 The SARS-CoV-2 hCoV-19/Finland/THL-202117309/2021 (delta strain B.1.617.2) and the  
149 mouse-adapted strain MaVie (18) were propagated in VeroE6-TMPRSS2 cells (kidney  
150 epithelial cells expressing the transmembrane protease serine 2) (19) grown in DMEM  
151 supplemented with 10% inactivated FCS, 100 IU/mL Penicillin, 100  $\mu$ g/mL Streptomycin  
152 and 2 mM L-glutamine at  $37^{\circ}\text{C}$ . The virus was purified from supernatants by  
153 ultracentrifugation (SW28 rotor, 27,000 rpm, 90 min,  $+4^{\circ}\text{C}$ ) through a 0.22  $\mu$ m-filtered 30%  
154 ultra-pure sucrose cushion (in PBS), to obtain virus preparations free of cell culture  
155 contaminants. Virus titers were calculated by the median tissue culture infectious dose  
156 (TCID<sub>50</sub>) after assessing cytopathic effects by crystal violet staining of cell cultures infected  
157 for 5 days with serially diluted virus.

158

#### 159 **RNA sequencing**

160 Neutrophils isolated from different cohorts comprised three PMN groups (severe COVID-19,  
161 mild COVID-19, and healthy controls), and one LDG group (given that these cells were rare  
162 in mild COVID-19 patients and HC, only LDGs from patients with severe COVID-19 were  
163 included).

164 cDNA synthesis from total RNA was performed according to Takara SMARTseq v4 Ultra-  
165 low input RNA kit for Sequencing user manual (Takara Bio, Mountain View, CA, USA)  
166 followed by Illumina Nextera XT Library preparation according to Illumina Nextera XT  
167 Reference Guide (Illumina, San Diego, CA, USA). UDI index setup was used for the Nextera  
168 XT libraries. Library quality check was performed using LabChip GX Touch HT High  
169 Sensitivity assay (PerkinElmer, USA) and libraries were pooled based on the concentrations  
170 acquired from the assay. The pooled libraries were quantified for sequencing using KAPA  
171 Library Quantification Kit (KAPA Biosystems, Wilmington, MA, USA) and sequenced on  
172 the Illumina NovaSeq6000 system for 200 cycles using S1 flow cell (Illumina, San Diego,  
173 CA, USA). Read length for the paired-end run was 2x101 bp.

174

#### 175 **RNA data analysis**

176 Principal Component Analysis (PCA) was performed on the normalized gene expression  
177 matrix using the Chipster software (20) to identify patterns in the data and reduce the  
178 dimensionality of the dataset. The top principal components were selected based on the  
179 percentage of variance explained. For enrichment analyses, Gene Set Enrichment Analysis  
180 (GSEA) and Over-Representation Analysis (ORA) were performed on the top 5000 DE genes  
181 identified by DESeq2 (adjusted P value < 0.05, log<sub>2</sub>FC >1) using ExpressAnalyst (21).  
182 GSEA was used to identify enriched signaling pathways using the Reactome database, while  
183 ORA was used to identify enriched pathways using the KEGG database. The resulting p-



184 values were corrected for multiple testing using the Benjamini-Hochberg method, and  
185 pathways with a corrected p-value <0.05 were considered significant.

186 To visualize the expression patterns of the differentially expressed (DE) genes, the data was  
187 analyzed using the AltAnalyze software (22), which selected the top 95 genes based on  
188 correlation and determined the heatmap clustering, using the Euclidean distance metric and  
189 the complete linkage method. Then, the obtained heatmap was re-generated using  
190 *heatmapper.ca* (23) for better visualization.

191 CIBERSORTx, a machine learning algorithm that infers cell type proportions using a  
192 reference gene expression matrix of known cell types (25) was used to perform RNA-seq  
193 deconvolution on the gene expression data to estimate the abundance of immune cell types in  
194 the samples (24). The signature matrix used was taken from Lasalle *et al.* (8). This reference  
195 matrix made use of a published whole-blood single-cell dataset (9), and included the main  
196 immune cell types: monocytes, NK cells, T lymphocytes, B lymphocytes, plasmablasts and  
197 neutrophils, the latter subclassified into mature and immature. The smaller subsets of  
198 granulocytes (eosinophils and basophils) are not considered separately and are most likely  
199 categorized as neutrophils in the bulk data deconvolution. Nonetheless, the resulting cell type  
200 proportions were used to compare the immune cell composition between groups.

201 Additionally, the determination of sample purity (>80% of “mature neutrophils” for PMNs or  
202 “immature neutrophils” for LDGs) served as a limiting parameter for the visualization of  
203 differentially expressed inflammasome related genes from the RNA sequencing results,  
204 which were selected and graphed in a heatmap using *heatmapper.ca* (23), clustered by  
205 complete linkage and ordered by Spearman’s rank.

206

207 **Volcano Plots**

208 To visualize differentially expressed (DE) genes between groups from human and mice  
209 RNA-seq results previously identified by DESeq2, a volcano plot was generated using  
210 GraphPad Prism. Genes with a P-adjusted value (padj or FDR) <0.05 were considered  
211 significant. Similarly, RNA sequencing data from GSE93996 (25) was reanalyzed, and all  
212 DE genes in ATRA-differentiated HL-60 cells were visualized in a volcano plot.

213

#### 214 **Single cell transcriptomics data analysis**

215 This study made use of the “COVID-19 Immune Atlas: integration of 5 public COVID-19  
216 PBMC single-cell datasets” available online (26). This standardized data collection contains  
217 cells from different assays (10x 3' v2, 10x 3' v3, 10x technology and Seq-Well) and consists  
218 of a total of 239,696 cells from the peripheral blood, 3,693 of which are neutrophils. These  
219 neutrophils were further subclassified as mature (59%) and immature (41%), based on the  
220 immune atlas predetermined cell classes. This was confirmed by a CD16b expression in  
221 mature neutrophils, and a higher CD66b expression in the immature population. This data  
222 was obtained from and analyzed in the Chan Zuckerberg CELLxGENE platform (26).

223

#### 224 **Reverse transcription and quantitative PCR (RT-qPCR) for human selected human** 225 **genes**

226 Total RNA was extracted from unstimulated or *ex vivo* stimulated PMNs using the Trizol  
227 reagent (Invitrogen, USA) according to the manufacturer’s protocol. Subsequently, cDNA  
228 synthesis was performed using the RevertAid RT Reverse Transcription Kit (Thermo  
229 Scientific, USA) as per the manufacturer's instructions. Quantitative PCR (qPCR) was  
230 performed using the Stratagene model (Agilent Technologies) and SYBR Green/ROX master  
231 mix (Thermo Scientific, USA). The primer sequences for qPCR are presented in  
232 Supplementary Table S1.

233 Primer specificity was confirmed using melting curve analysis and dissociation curves. The  
234 relative expression levels of the genes of interest were calculated using the  $2^{-\Delta\Delta CT}$  method  
235 and normalized to the expression of the housekeeping gene GAPDH. Baseline gene  
236 expressions of unstimulated samples were statistically assessed using the Mann-Whitney test,  
237 while the two-way ANOVA Tukey's multiple comparisons test was performed for the *ex vivo*  
238 stimulated samples.

### 239 **Mouse infections**

240 Experimental procedures were approved by the Animal Experimental Board of Finland  
241 (license number ESAVI/28687/2020). Female BALB/c mice (Envigo, Indianapolis, IN, USA;  
242 7 to 8 weeks, n = 36 in total) were transferred to the University of Helsinki biosafety level-3  
243 (BSL-3) facility and acclimatized to individually ventilated biocontainment cages (ISOcage;  
244 Scanbur, Karl Sloanestran, Denmark) for 7 days with *ad libitum* water and food (rodent  
245 pellets). For subsequent experimental infection, the mice were placed under isoflurane  
246 anesthesia and inoculated intranasally with 50  $\mu$ L of SARS-CoV-2 MaVie strain ( $5 \times 10^5$   
247 TCID<sub>50</sub>/animal) or PBS (mock-infected control). Daily weighting of all mice was performed,  
248 and their well-being was carefully monitored for signs of illness (e.g., changes in posture or  
249 behavior, rough coat, apathy, ataxia). Euthanasia was performed by cervical dislocation under  
250 terminal isoflurane anesthesia. All animals were dissected immediately after euthanasia, and  
251 the lungs were sampled for multiple downstream analyses. The infections were performed as  
252 3 separate experiments (exp) with 12 mice each: 1) Exp 1 included 8 mice infected with  
253 MaVie and 4 mock infected mice. At 2 days post infection (dpi), 4 infected and the mock  
254 infected mice were euthanized; the remaining infected mice were euthanized at 4 dpi. The  
255 right lung was sampled for virus-specific RT-qPCR (1/5) and neutrophil isolation (4/5), the  
256 left lung was fixed for histological and immunohistochemical examination. 2) Exp 2 included  
257 8 infected and 4 mock infected mice of which half were euthanized at 2 dpi and 4 dpi,

258 respectively. From these mice, both lung lobes were subjected to neutrophil isolation. 3) Exp  
259 3 included 8 mice that were infected and immediately inoculated intraperitoneally with 250  
260  $\mu\text{g}$  of anti-mouse IFNAR-1 ( $n = 4$ ) or IgG1 isotype control ( $n = 4$ ) (Bio-X-Cell, New  
261 Hampshire, USA), and 4 mock-infected animals. All mice were euthanized at 2 dpi. Each 1  
262 1/5 of the left lobe was processed for virus-specific RT-qPCR and histology and  
263 immunohistochemistry respectively. The remaining approx. 80% of the lungs served for  
264 neutrophil isolation.

### 265 **Neutrophil isolation from mouse lungs**

266 Neutrophil isolation was performed from the lungs of all mice. The dissected lung tissue was  
267 chopped into small pieces using scissors and enzymatically digested with a cocktail of  
268 Liberase (50  $\mu\text{g}/\text{ml}$ ; Roche #05401020001 from Merck) and DnaseI (100  $\mu\text{g}/\text{ml}$ ; Roche  
269 #11284932001 from Merck) in RPMI-1640 for 30 min at 37 °C. The resulting homogenate  
270 was diluted 10-fold in R10 and passed through a 70  $\mu\text{m}$  Cell strainer (Pluriselect) to obtain a  
271 single-cell suspension. Neutrophils were isolated by positive selection using Ly6G-binding  
272 magnetic beads and MS columns according to the manufacturer's recommendations (Miltenyi  
273 Biotec). Neutrophils were isolated with a purity exceeding 95% based on flow cytometry  
274 analysis of Ly6G expression.

275

### 276 **RNA sequencing of mouse neutrophils**

277 Mouse neutrophils were isolated, lysed in Trizol (Thermo Scientific) and the RNA extracted  
278 in the liquid phase using chloroform. RNA isolation was carried out using the Rneasy micro  
279 kit (Qiagen). Isolated RNA (1 ng) underwent whole transcriptome sequencing with  
280 ribodepletion. Briefly, RNA sequencing was performed using the Illumina Stranded with  
281 RiboZero library preparation method. Sample quality and integrity were assessed using

282 TapeStation RNA analysis. Sequencing was conducted on the Illumina NextSeq platform,  
283 followed by standard bioinformatics analysis for gene expression quantification.

284 The service was provided by the Biomedicum Functional Genomics Unit at the Helsinki  
285 Institute of Life Science and Biocenter Finland at the University of Helsinki.

286

### 287 **RT-qPCR of mouse samples**

288 RNA was extracted from dissected lung samples (1/10 of the whole lung) of mice in Exp 1  
289 and Exp 3 as well as isolated neutrophils using Trizol (Thermo Scientific) following the  
290 manufacturers' instructions. The isolated RNA was directly subjected to one-step RT-qPCR  
291 analysis based on a previously described protocol using primer-probe sets detecting the viral  
292 genome encoding for the RNA-dependent RNA polymerase (RdRp) (27), subgenomic E (28)  
293 as well as mouse caspase1, IL1b and GAPDH (Applied biosystems #Mm00438023\_m1,  
294 #Mm00434228\_m1 and #Mm99999915\_g1 respectively, Thermo scientific). The PCRs were  
295 performed with TaqPath 1-step master mix (ThermoFisher Scientific) using AriaMx  
296 instrumentation (Agilent, Santa Clara, CA, USA).

297

### 298 **Histology and immunohistochemistry**

299 From animals in Exp 1 and Exp 3 the whole left lung (Exp 1) or 1/5 of the left lung (Exp 3)  
300 were trimmed for histological examination and routinely paraffin wax embedded.  
301 Consecutive sections (3  $\mu$ m) were prepared and routinely stained with hematoxylin-eosin  
302 (HE) or subjected to immunohistochemistry (IHC) for the detection of SARS-CoV-2  
303 nucleoprotein (NP) (29) and Ly6G (neutrophil marker); for Exp 3, a further section of the  
304 infected lungs was stained for histone H3 (NET marker) (30). All stains followed previously  
305 published protocols (31).

306

307 **Morphometric analyses**

308 For quantification of SARS-CoV-2 antigen expression and the extent of neutrophil influx into  
309 the lungs, a morphometric analysis was undertaken on the slides stained for SARS-CoV-2 NP  
310 and Ly6G, respectively. The stained slides were scanned using NanoZoomer 2.0-HT  
311 (Hamamatsu, Hamamatsu City, Japan), and several sections of the lung of each animal were  
312 quantitatively analysed using the Visiopharm 2022.01.3.12053 software (Visiopharm,  
313 Hoersholm, Denmark). The morphometric analysis served to quantify the area, in all lung  
314 sections of an animal, that showed immunostaining for viral NP and Ly6G, respectively. In  
315 Visiopharm, for each section, the lung was manually outlined and annotated as a Region Of  
316 Interest (ROI), manually excluding artifactually altered areas. The manual tissue selection  
317 was further refined with an Analysis Protocol Package (APP) based on a Decision Forest  
318 classifier, with the pixels from the ROI being ultimately classified as either “Tissue” or  
319 “Background”. This new “Tissue” ROI, regrouping the different lung samples analysed for  
320 each animal, was further quantified by executing two APPs successively. The first APP was  
321 based on a Threshold classifier and served to detect and outline areas with immunostaining.  
322 The second APP then measured both the surface of the immunostained area ( $\mu\text{m}^2$ ) and the  
323 surface of the “Tissue” ROI ( $\mu\text{m}^2$ ). The percentage of immunostained area (%), expressed as  
324 the ratio between the immunostained area and the total area, was obtained for each animal in  
325 Excel (Microsoft Office 2019; Microsoft, Redmond, Washington, United States), according  
326 to the following formula:  $([\text{positive area } (\mu\text{m}^2)] / [\text{total area } (\mu\text{m}^2)]) \times 100$ .

327

328 **Statistical analyses**

329 Statistical analysis was performed using GraphPad Prism 8.3 software (GraphPad Software,  
330 San Diego, CA, USA) and R software v3.6.3 (R core team). Statistically significant  
331 correlations between parameters were assessed by calculating Spearman’s correlation

332 coefficients, and differences between groups were assessed with Mann-Whitney, Kruskal-  
333 Wallis or ordinary one-way or 2-way ANOVA tests, depending on sample distribution and  
334 the number of groups analyzed.

335 **Results**

336 **Unsupervised RNA-seq analysis reveals a gene expression signature of circulating**  
337 **neutrophils in COVID-19 that is strongly influenced by maturity**

338

339 With our recent findings on increased frequencies of low-density granulocytes (LDGs,  
340 isolated from the PBMC fraction) during COVID-19 and their likely relevant role in disease  
341 progression (7), we sought to understand in more detail how the transcriptomic profile of  
342 LDGs differs from their higher “normal” density counterpart, the circulating  
343 polymorphonuclear cells (PMNs) (32), typically consisting mainly of mature neutrophils.  
344 Neutrophils isolated from different cohorts comprised three PMN groups (severe COVID-19,  
345 mild COVID-19, and healthy controls), and one LDG group. We explored gene expression  
346 through RNA sequencing (RNA-seq) and confirmed the distinctive gene signature of LDGs  
347 by principal component analysis (PCA) (Figure 1A), which revealed that the gene expression  
348 patterns of COVID-19 LDGs differed from those of all PMNs regardless of the patients’  
349 disease state.

350 Functional enrichment analyses through gene overrepresentation and gene-set enrichment  
351 analyses (ORA and GSEA, respectively) compared LDGs with PMNs from severe COVID-  
352 19 patients (Figure 1B). When considering the top 5000 differentially expressed genes  
353 (DEG), DNA replication and cell cycle were the most overrepresented pathways identified by  
354 ORA (Figure 1B), which supported our previous findings suggesting LDGs to be  
355 predominantly immature cells (7). However, the next statistically significant result was an  
356 underrepresentation of the NLR signaling pathway genes in LDGs in contrast with PMNs,  
357 highlighting that LDGs have an inflammatory profile that differs from that of PMNs, also  
358 depicted in the GSEA (Figure 1B). Briefly, type I and II interferon signaling were among the  
359 most significantly enriched gene sets in PMNs compared to LDGs. Further analysis showed



360 that PMNs from severe COVID-19 patients had significantly enriched DEGs in inflammatory  
361 pathways such as NLR, tumor necrosis factor (TNF), retinoic acid-inducible gene-I (RIG-I)  
362 like, autophagy, MAPK and JAK/STAT signaling pathways compared to either HC PMNs or  
363 severe COVID-19 LDGs (Supplementary Fig. 1A-D). Interestingly, many of the observed  
364 DEGs were linked to inflammasome formation (Supplementary Fig. 1E-F). However, mild  
365 COVID-19 PMNs did not significantly differ from HC PMNs in their inflammatory profile  
366 (Supplementary Fig. 1G-H).

367 Additionally, we performed unsupervised Iterative Clustering and Guide Gene Selection  
368 (ICGS), which identified the top DEGs and classified the samples into two major clusters: a  
369 first one containing all isolated LDG samples, and a second one comprising all isolated PMN  
370 samples (Figure 1C). The former cluster consisted of many neutrophil marker genes (e.g.  
371 *CEACAM8*, *MMP8*, *DEFA*), while in the latter cluster the most significantly upregulated  
372 genes in the severe COVID-19 subgroup were mainly interferon inducible (e.g. *OAS1*, *OAS2*,  
373 *IFI44L*, *IFITM3*, *IFIT2*) as well as some inflammasome related (*CASP5*, *CARD16*) genes.

374

375

376 **Mature neutrophils from severe COVID-19 display a strong IFN-related gene**  
377 **expression signature**

378 To gain a comprehensive understanding of the cellular composition within PMN and LDG  
379 fractions, we performed a deconvolution of the RNA-seq data, which verified that most cells  
380 present in the samples were neutrophils. This analysis also demonstrated that cells in the  
381 LDG fraction were predominantly immature neutrophils, meanwhile PMNs were composed  
382 of mainly mature neutrophils (Figure 2A). Subsequently, gene expression analysis of PMNs  
383 and LDGs containing high purity of mature neutrophils and immature neutrophils (over  
384 80%), respectively, confirmed that mature neutrophils from severe COVID-19 displayed an

385 increased expression of type I IFN related genes, while immature neutrophils from severe  
386 COVID-19 distinctively lacked this signature (Figure 2B).

387

### 388 **Inflammasomes are activated in severe COVID-19 PMNs, but not directly by SARS-** 389 **CoV-2**

390 Looking more closely into PMN fractions, ORA identified the inflammasome related NOD-  
391 like and RIG-like receptor signaling pathways among the most significantly overrepresented  
392 pathways, differentially expressed in severe COVID-19 PMNs versus HC PMNs (Figure 3A)  
393 or mild COVID-19 PMNs (Figure 3B). The increased expression of selected IFN-I (*OAS1*,  
394 *OAS2*, and *IFIT1*) and inflammasome related genes (*CASP1*, *CASP5*, *NLRC5* and *NAIP*) was  
395 confirmed by RT-qPCR. However, some inflammasome related genes (*IL-1 $\beta$* , *NLRP3* and  
396 *NLRC4*) were seemingly downregulated, although not statistically significant (Supplementary  
397 Fig. 2).

398 Given the strong upregulation of many inflammasome related genes during severe COVID-  
399 19, we assessed whether PMNs exhibit active inflammasome formation *in vivo*. To evaluate  
400 spontaneous inflammasome mediated cytokine secretion, fresh PMNs isolated from severe  
401 COVID-19 patients and HC were cultured *ex vivo* overnight. We measured the levels of IL-  
402 1 $\beta$  and IL-18 in the supernatant and found that IL-1 $\beta$  secretion was significantly increased in  
403 the supernatant of severe COVID-19 PMNs compared to HC PMNs (Figure 3C), whereas the  
404 IL-18 levels did not differ significantly (Figure 3D). Additionally, since SARS-CoV-2 viral  
405 particles were previously implicated to induce inflammasome formation in macrophages (17),  
406 the IL-1 $\beta$  and IL-18 levels after HC PMNs exposure to SARS-CoV-2 were also assessed but  
407 no significant effects in the secretion of these cytokines were observed (Figure 3E, F).

408 The spontaneous secretion of IL-1 $\beta$  by COVID-19 PMNs suggests that these cells are  
409 actively producing and releasing IL-1 $\beta$  through inflammasome formation which is dependent  
410 on caspase1 activity (33). We assessed caspase1 activity in response to the second signal  
411 required for inflammasome activation, induced by nigericin, and observed increased caspase1  
412 activity in severe COVID-19 PMNs compared to HC PMNs (Figure 3G). These findings  
413 suggest that severe COVID-19 PMNs have an increased capacity for inflammasome  
414 activation, potentially due to an existing priming signal during acute disease *in vivo*.  
415 However, no significant difference in caspase1 activity between non-exposed and virus-  
416 exposed PMNs were observed (Figure 3G), indicating that caspase1 activation in COVID-19  
417 PMNs is not directly triggered by the virus.

418

419 **Activation of neutrophil inflammasome related pathways during respiratory distress is**  
420 **not specific to COVID-19**

421 We also reanalyzed the RNA-seq data previously generated by LaSalle *et al.* (8), focusing on  
422 neutrophil transcriptomics in patients with COVID-19 as compared to non-COVID-19  
423 patients, as well as to healthy controls. The non-COVID-19 patients were presented with  
424 acute respiratory distress and clinical concern for COVID-19 but tested negative for SARS-  
425 CoV-2 by PCR. Our analysis included IFN- $\alpha$  response, IL-1 $\beta$  production, TLR signaling,  
426 NLRP3 inflammasome, and pyroptosis pathways, using the Gene Ontology (GO) database;  
427 the NLR signaling pathway using the Kyoto Encyclopedia of Genes and Genomes (KEGG)  
428 database; and inflammasome pathway using the REACTOME database (Figure 4). These  
429 pathways were significantly enriched in COVID-19 patients, supporting our findings.  
430 Importantly, the genes from the above-mentioned pathways were also induced in non-  
431 COVID-19 patients, suggesting that these pathways represent a general neutrophil response  
432 to inflammatory stimuli rather than a COVID-19 specific response.

### 433 **Type I IFNs prime PMNs for inflammasome activation**

434 Since PMNs from COVID-19 patients concomitantly display a strong IFN-I signature (Figure  
435 2B) and an increased propensity for inflammasome activation, we hypothesized that IFN-I  
436 could act as the priming signal for PMN inflammasomes during COVID-19. Isolated HC  
437 PMNs were stimulated *ex vivo* with exogenous IFN-I and the well-described inflammasome  
438 priming (1<sup>st</sup> signal) and activator (2<sup>nd</sup> signal) agents LPS and nigericin, respectively (34, 35).  
439 After stimulation, both priming signals induced pro-IL-1 $\beta$  (31 kDa) in the cell lysates,  
440 followed by the release of active IL-1 $\beta$  (17 kDa) into the supernatant in response to nigericin  
441 (Figure 5A), confirming the ability of IFN-I to prime PMNs for inflammasome activation.

442 To assess inflammasome formation in circulating neutrophils during COVID-19, PMNs from  
443 HC and COVID-19 patients underwent similar stimulation assays as above, followed by IL-  
444 1 $\beta$  measurement from supernatants by ELISA. In addition, to further assess the role of  
445 SARS-CoV-2 virus particles in neutrophil inflammasome activation, HC PMNs were  
446 cultured in the presence of purified viruses (10 infectious units/PMN). HC PMNs responded  
447 to both LPS and IFN-I by increasing their IL-1 $\beta$  secretion, which was exponentiated after  
448 exposure to nigericin (Figure 5A), confirming the ability of IFN-Is to prime for  
449 inflammasome assembly in PMNs, albeit less efficiently than LPS. Interestingly, COVID-19  
450 PMNs produced less IL-1 $\beta$  than HC PMNs upon exogenous inflammasome activation primed  
451 by either LPS or IFN-I, while SARS-CoV-2 particles did not have any effect on PMN  
452 inflammasome activation (Figure 5B). As with 24-h cultures (Figure 3D), we did not detect  
453 any significant changes in IL-18 secretion in either HC or COVID-19 PMNs (Supplementary  
454 Fig. 3A). However, myeloperoxidase (MPO) responded to nigericin indistinctively between  
455 COVID-19 PMNs and HC PMNs, and therefore the observed diminished IL-1 $\beta$  release by  
456 COVID-19 PMNs is not due to general cellular inertia but may be specific to the *ex vivo*

457 induced inflammasome pathway. Furthermore, additional stimulation assays in the presence  
458 of the NLRP3 inhibitor MCC950 (Figures 5D-E) and caspase1 inhibitor YVAD  
459 (Supplementary Fig. 3B) confirmed that induced IL-1 $\beta$  secretion is dependent on canonical  
460 NLRP3 inflammasome activation. However, unlike IL-1 $\beta$  (Supplementary Fig. 3C),  
461 increased IL-18 secretion was not detectable even after 24-h stimulation (Supplementary Fig.  
462 3D). Furthermore, the observed residual IL-18 was not affected by inflammasome inhibitors,  
463 suggesting its secretion to be unrelated to inflammasome activity in PMNs.

464 We further assessed the specificity of inflammasome activation by measuring LDH and IL-8  
465 levels in the supernatants from the same cells and under the same experimental conditions as  
466 shown in Figures 5D-E. The measurements of the former were done to assess inflammasome  
467 mediated cell death by pyroptosis in response to nigericin, while the latter was assessed to  
468 demonstrate the responsiveness of PMNs to an inflammasome unrelated inflammatory  
469 cascade. As with IL-1 $\beta$  secretion, COVID-19 PMNs were less responsive than HC PMNs to  
470 nigericin- and LPS-mediated LDH (Figure 5F) and IL-8 (Figure 5G) release, respectively.  
471 This suggests that COVID-19 PMNs are generally poorly responsive to inflammatory stimuli.

472 To examine this reduced responsiveness to external inflammatory priming, we evaluated the  
473 inflammasome related gene expression following *ex vivo* stimulation with IFN-I or LPS  
474 (Figure 5H-I and Supplementary Fig. 3D-G). OAS1 gene, an interferon stimulated gene  
475 (ISG), showed significant upregulation by IFN-I in COVID-19 PMNs as compared to HC  
476 PMNs (Figure 5H), while the inflammasome related genes IL-1 $\beta$  (Figure 5I), CASP1 (Figure  
477 5J) and NLRC5 (Figure 5K) were more efficiently induced in HC PMNs than COVID-19  
478 PMNs. This suggests that the inflammasome defect in COVID-19 PMNs is at the  
479 transcriptional level when using IFN-I as the priming factor, while high OAS1 gene  
480 expression indicates transcriptional defect is restricted to individual genes.

481 **Association between *ex vivo* inflammasome activation and disease severity**

482 Our analysis of the association between *ex vivo* inflammasome activation (caspase1 activity  
483 and IL-1 $\beta$  release) and clinical markers of disease severity, including neutrophil responses,  
484 revealed intriguing links. Calprotectin is marker of neutrophil activation or death (36) but  
485 also potentially activates the inflammasome (37). A significant positive correlation between  
486 calprotectin plasma levels and PMN caspase1 activity (Figure 6A-B) underscores this latter  
487 possibility and highlights the interplay between inflammation and inflammasome activation  
488 in PMNs of COVID-19 patients. Furthermore, the negative association of PMN IL-1 $\beta$  levels  
489 (after *ex vivo* stimulation) with disease severity (WHO ordinal scale, Figure 6A) and patient  
490 neutrophil counts (Figure 6A, C) supports the exhaustion hypothesis, wherein PMNs from  
491 severe COVID-19 patients may be less responsive to stimuli due to prior *in vivo* activation.  
492 While these findings provide intriguing insights into the complex interplay between  
493 calprotectin release, caspase1 activity, and inflammasome activation in COVID-19,  
494 additional research is required to further elucidate these connections.

495 **LDGs differ from PMNs in gene expression and release of inflammasome related**  
496 **interleukins**

497 To assess the inflammasome related inflammatory profile of COVID-19 LDGs in comparison  
498 to PMNs, we analyzed the differential expression of inflammasome related genes using  
499 RNA-seq (Figure 7A). LDGs differed significantly from PMNs, with the most striking  
500 difference being their increased expression of IL-18 and NLRC4, whereas PMNs displayed  
501 higher levels of IL-1 $\beta$ , NLRP3 and caspases 1, 4 and 5. Single cell sequencing data from the  
502 COVID-19 immune atlas confirmed our transcriptomic results (Figure 7B), from which a  
503 detailed gene by gene analysis of the most relevant inflammasome related genes is shown  
504 (Figure 7C and Supplementary Fig. 4). Briefly, PYCARD gene coding for the ASC protein

505 was expressed similarly in mature and immature neutrophils (Supplementary Fig. 4),  
506 confirming that both cell types have inflammasome forming capacity. However, most of the  
507 inflammasome gene expressions differed significantly and in the same manner as in our  
508 transcriptomic analysis.

509

510 We conducted *ex vivo* stimulation assays using LDGs isolated from COVID-19 patients,  
511 similar to the approach used for PMNs described earlier. Like PMNs, IL-1 $\beta$  secretion by  
512 LDGs was elevated in the presence of a priming signal (IFN-I or LPS), which exponentially  
513 increased when the inflammasome activation signaling molecule nigericin was added (Figure  
514 7D). Contrary to PMNs and in line with the transcriptomics data, an increased IL-18 secretion  
515 was detected (Figure 7E). Additionally, the secretion of both ILs by LDGs was inhibited in  
516 the presence of inflammasome specific inhibitors MCC950 and YVAD (Figure 7F-G).

517 These findings suggested that the outcome of neutrophil inflammasome activation varies  
518 based on cellular maturation state. To explore this further, we conducted *in vitro* stimulation  
519 studies using differentiated HL-60 cells, an immature neutrophil-like model (38). Similar to  
520 LDGs from COVID-19 patients, HL-60 displayed comparable IL-18 secretion pattern upon  
521 LPS or IFN-I stimulation and nigericin-induced activation. Notably, their IL-1 $\beta$  release was  
522 only detected with LPS priming (Figures 7F-G). Furthermore, consistent with transcriptomic  
523 analysis revealing an upregulation of inflammasome related genes upon differentiation  
524 (Figure 7H), the capacity of HL-60 cells to secrete inflammasome related cytokines was  
525 differentiation-dependent (data not shown). Overall, these findings suggest that neutrophils  
526 may lose the ability to secrete IL-18 during maturation, and release of neutrophil-derived IL-  
527 18 occurs primarily in disease states associated with extensive granulopoiesis and increased  
528 immature granulocyte counts in the blood, like COVID-19 (39).

529

### 530 **Neutrophils are recruited to the lungs in SARS-CoV-2 infected mice**

531 Hamsters and human ACE2 expressing mice infected with SARS-CoV-2 develop pulmonary  
532 inflammation including neutrophil recruitment (40–42). To further assess the role of  
533 neutrophils in COVID-19, we utilized a recently developed SARS-CoV-2 mouse model (18).  
534 This model employs the MaVie strain, serially passaged in mouse lungs and causing  
535 pneumonia similar to human COVID-19 in wild-type BALB-C mice (18). Infected mice  
536 started losing weight by day 2 post-infection, with some mice reaching the clinical endpoint  
537 of 20% weight loss by day 4 (Supplementary Fig. 5A). Viral loads were significantly higher  
538 at 2 dpi than 4 dpi (Figure 8A), and viral antigen expression, widespread at 2dpi in  
539 bronchioles and alveoli, matched this pattern (Figure 8B and D). The extensive viral  
540 replication at 2 dpi was associated with degeneration of infected epithelial cells, most  
541 prominent in the respiratory epithelium, accompanied by neutrophil (Ly6G+) infiltration  
542 (Figure 8D) and a significant increase in the number of neutrophils in the lungs of infected  
543 mice compared to PBS-inoculated mice (Figure 8C). Neutrophil numbers significantly  
544 decreased by 4dpi but remained higher than controls (Figure 8C). Detailed information on the  
545 histological and immunohistochemical features of these mice is provided in Supplementary  
546 Table S2. Together, these findings suggest a pivotal role of neutrophils in clearing the virus  
547 in SARS-CoV-2 infected mice.

548

### 549 **Neutrophils from SARS-CoV-2 infected mice display IFN-I dependent caspase1** 550 **activation**

551 We isolated neutrophils from the lungs of infected mice at 2 and 4 dpi, as well as from non-  
552 infected mice (inoculated with PBS) for transcriptomic analysis by RNA-seq (Exp 1). PCA  
553 showed distinct differences between neutrophils from infected and non-infected mice, with  
554 slight variation between the 2 and 4 dpi time points (Figure 9A). These differences were



555 reflected in many DEGs, including several IFN-I responsive and inflammasome related  
556 genes, which showed strong upregulation at 2 dpi with slightly lower but still significantly  
557 elevated levels at 4 dpi, compared to non-infected mice (highlighted in the DEG heatmap;  
558 Figure 9B). The volcano plot (Figure 9C) provided a comprehensive view of the DEG pattern  
559 between neutrophils from SARS-CoV-2 infected and mock-infected mice. In addition to  
560 confirming the upregulation of IFN-I responsive and inflammasome related genes observed  
561 in the heatmap, the plot revealed a broader transcriptional response to viral infection with  
562 several additional DEG.

563 Next, we investigated if neutrophils from SARS-CoV-2 infected mice showed increased  
564 inflammasome formation, similar to PMNs from COVID-19 patients. Neutrophils from  
565 infected mice, harvested at 2 and 4 dpi, displayed increased caspase1 activity upon nigericin  
566 stimulation, compared to neutrophils from non-infected mice (Exp 2; Figure 9D). To assess  
567 the role of IFN-I, we inoculated mice with an IFN-I blocking anti-IFNAR monoclonal  
568 antibody or an isotype control antibody post-infection (Exp 3). Remarkably, neutrophils from  
569 anti-IFNAR treated mice showed diminished nigericin-induced caspase1 activity (Figure 9E).  
570 Furthermore, caspase1 and IL-1 $\beta$  gene expressions were lower in anti-IFNAR treated than  
571 isotype treated mice (Figure 9F-G). Taken together, IFN-I appears to be responsible for the  
572 increased caspase1 activity in neutrophils of infected mice.

573 Histology of isotype-treated mice and anti-IFNAR treated mice lungs showed comparable  
574 features (Supplementary Fig. 5C) as infections without antibody (Exp 1; Figure 8B-D).  
575 Regardless of treatment, some neutrophils in infected mice displayed degeneration and  
576 NETosis evidenced by histone H3 staining (Supplementary Fig. 5C; Supplementary Table  
577 S2), and viral loads remained consistent between anti-IFNAR or IgG1 isotype control treated  
578 mice (Supplementary Fig. 5B). Taken together, blocking IFN-I signaling did not alter virus

579 replication, virus-induced pathological changes, or early neutrophil recruitment following  
580 infection.

## 581 Discussion

582 Neutrophils, the largest cell population of the host immune system, are rapidly recruited to  
583 sites of infection and play an important role in orchestrating an early immune response (43,  
584 44). The relevance of neutrophils in viral infections became increasingly apparent during the  
585 COVID-19 pandemic, as they have been shown to be key mediators of the observed  
586 pathological processes (45).

587 This study sheds light on the potential involvement of the inflammasome pathway in  
588 COVID-19, particularly by demonstrating its activation in neutrophils during SARS-CoV-2  
589 infection. Our investigation of the inflammatory profile of neutrophils as the dominant  
590 population of peripheral blood polymorphonuclear cells (PMNs) revealed an increased ability  
591 of neutrophils from severe COVID-19 patients for inflammasome assembly as evidenced by  
592 their transcriptional profile, spontaneous release of IL-1 $\beta$ , and elevated caspase1 activity.  
593 These findings are consistent with previous reports indicating activation of the NLRP3  
594 inflammasome and ASC specks in circulating neutrophils during acute COVID-19 (14, 16).  
595 Furthermore, despite showing increased caspase1 activity, neutrophils from COVID-19  
596 patients exhibited diminished soluble IL-1 $\beta$  production upon exogenous activation of the  
597 NLRP3 inflammasome pathway compared to healthy controls, which suggests that this  
598 pathway is “exhausted” due to prior activation during the disease. Mechanistically, our  
599 findings show that IFN-I, elevated in COVID-19 patients (46, 47), can prime inflammasome  
600 formation in neutrophils. Transcriptomic analyses revealed that circulating neutrophils during  
601 severe COVID-19 show increased expression of IFN-responsive genes, suggesting  
602 inflammasome priming by IFN-I also *in vivo* during COVID-19 (48). Furthermore, the study  
603 found that immature neutrophils, which are prevalent in low-density granulocyte fraction  
604 (LDGs), exhibit unique inflammasome gene expression and outcomes compared to mature

605 neutrophils (PMNs). LDGs release IL-18 and upregulate distinct inflammasome related genes  
606 but lack the IFN-I signature seen in PMNs during COVID-19, indicating lower  
607 responsiveness to IFN-I, and supported by less efficient IFN-I mediated inflammasome  
608 priming of LDGs *ex vivo*.

609 SARS-CoV-2 infected mice also showed increased neutrophil caspase1 activity, reversible by  
610 an IFN-I receptor (IFNAR) blocking antibody. Transcriptional analysis revealed a robust  
611 IFN-I signature and elevated expression of inflammasome genes encoding for caspase1 and  
612 IL-1 $\beta$  in neutrophils of infected mice, which were also inhibited by blocking IFNAR  
613 signaling, suggesting that IFN-I may also prime for inflammasome activation in mice.  
614 Notably, the anti-IFNAR treatment did not affect neutrophil recruitment or NETosis, which is  
615 consistent with another COVID-19 model using transgenic human ACE2, where IFNAR  
616 knockout inhibited recruitment of monocytes and lymphocytes, but not neutrophils, to  
617 infected lungs (49).

618 Inflammasomes were initially studied in macrophages, revealing a plethora of molecular  
619 mechanisms regulating inflammasome assembly (50). Macrophage inflammasome activation  
620 has emerged as a major factor also in COVID-19 (17). Interestingly, macrophage  
621 inflammasome activation was recognized to be IFN-I mediated in an experimental rhesus  
622 macaque COVID-19 model (51). However, due to the abundance of neutrophils compared  
623 with cells of monocyte/macrophage lineage (52, 53), the significance of neutrophil  
624 inflammasomes in COVID-19 is likely underestimated. Our results highlight inflammasomes  
625 as an additional important inflammatory mechanism in neutrophils (14), complementing their  
626 role in phagocytosis, reactive oxygen species generation, degranulation, and NETosis (32).

627 SARS-CoV-2 can directly activate inflammasomes in cells of the monocyte/macrophage  
628 lineage (17). Our study investigated whether SARS-CoV-2 can provide the first or second

629 signal for inflammasome activation in neutrophils. However, we found no evidence of direct  
630 virus-induced inflammasome activation in neutrophils. The difference between macrophages  
631 and neutrophils in their susceptibility to SARS-CoV-2 could depend on many factors. Both  
632 cell types express ACE2, the receptor for SARS-CoV-2, but may differ in ACE2 expression  
633 levels (54). Furthermore, the intracellular environment of macrophages is better suited for  
634 viral replication (55), while neutrophils focus on phagocytosis and antimicrobial responses  
635 (32, 56). Additionally, pathogen opsonization can trigger inflammasomes in macrophages  
636 (57) but is not a primary function of neutrophils. Therefore, our findings suggest neutrophil  
637 inflammasome activation in response to SARS-CoV-2 likely results from interactions with  
638 infected and/or dying cells in the lungs, rather than direct virus activation. To note, whether  
639 SARS-CoV-2 can induce neutrophil inflammasomes through immune complex-mediated  
640 mechanisms, as seen in monocytes/macrophages (17) remains to be determined.

641 In this study, we demonstrated IFN-I as the first signal for NLRP3 inflammasome activation  
642 in neutrophils. While prior research has explored IFN-inflammasome crosstalk (58), priming  
643 capacity of IFN-I remained unclear. While IFN-I promotes inflammasomes in epithelial cells  
644 (59) it can also dampen IL-1 $\beta$  in macrophages (60). Plausibly, initial IFN-I exposure may  
645 upregulate inflammasome genes, whereas prolonged activity could hinder IFN-I signaling via  
646 “negative feedback” loop, in line with our findings of inflammasome exhaustion in  
647 circulating neutrophils of severe COVID-19 patients.

648 Our study also unveiled distinct gene profiles in LDGs and PMNs from severe COVID-19  
649 patients. LDGs exhibited upregulation of genes related to DNA replication and cell cycle,  
650 indicating immaturity, and confirming our prior findings (7). Conversely, PMNs displayed  
651 heightened NLR signaling, suggesting a robust response to pathogens. While our study  
652 compared PMNs and LDGs, and the COVID-19 Immune Atlas single cell analysis

653 represented a broader classification of mature and immature neutrophils, the alignment of our  
654 results with the atlas provides further support for the distinct characteristics of these two  
655 neutrophil populations in severe COVID-19. Notably, IL-18 gene expression and secretion  
656 after *ex vivo* stimulation were higher in LDGs than PMNs. To note, PMN's lack of IL-18  
657 secretion is not due to lack of protein, as they constitutively express significant amounts  
658 intracellularly (61). This indicates a similarity between LDGs and monocytes/macrophages in  
659 inflammasome mediated IL-18 processing, possibly lost during neutrophil maturation.

660

661 The present study has some limitations worth discussing. Firstly, the relatively small human  
662 sample size may limit the generalizability of the findings. While RNA-seq provided valuable  
663 insights into gene expression profiles of PMNs and LDGs, we did not perform functional  
664 validation of the identified pathways in this study. Regarding our experimental SARS-CoV-2  
665 infected model, the high virus input might trigger robust immune responses that differ from  
666 typical human infections, and the short-lived virus replication in the applied model does not  
667 capture the effect of prolonged antigen exposure or the complex inflammatory milieu seen in  
668 human cases. The prominent role of neutrophils in the immune response to viral infections is  
669 widely recognized (43, 44) and it would be valuable to compare these findings to neutrophil  
670 responses in other viral respiratory infections.

671

672 Taken together, our findings provide valuable insights into neutrophil involvement in  
673 COVID-19 and possibly other viral respiratory infections. However, further research is  
674 needed to fully grasp the role of neutrophil inflammasomes in COVID-19 pathogenesis. This  
675 increased understanding may facilitate the development of targeted treatment approaches for  
676 COVID-19. The next steps involve validating the pathways and genes identified as potential  
677 therapeutic targets and assessing their COVID-19 specificity. Prospectively, these strategies

678 could be extended to address upcoming respiratory virus pandemics, where neutrophils and  
679 inflammasomes provide major pathogenic contributions.

## 680 **Contributors**

681 L.E.C.: conceptualization, data curation, formal analysis, investigation, software, validation,  
682 visualization, writing– original draft; S.T.J.: investigation, writing – review & editing; Sa.M.:  
683 investigation; Si.M.: investigation; R.K.: resources; L.K.: investigation, writing – review &  
684 editing; Ta.S.: resources; J-P.P.: resources; Anu.K.: funding acquisition, resources, writing –  
685 review & editing; E.K.: supervision, writing – review & editing; H.L.: resources; P.M.:  
686 resources, writing – review & editing; Anj.K.: investigation, methodology, supervision,  
687 validation, visualization, writing – review & editing; O.V.: funding acquisition, resources;  
688 To.S.: conceptualization, data curation, formal analysis, funding acquisition, investigation,  
689 methodology, project administration, supervision, validation, writing – original draft.

690

## 691 **Declaration of Competing Interest**

692 All authors declare no financial competing interests related to the study.

693

## 694 **Acknowledgements**

695

696 This work was financed by grants by the Academy of Finland to To.S. (321809), Anu.K.  
697 (336439 and 335527); grants by the Helsinki University Hospital funds to O.V. (TYH  
698 2021343); EU Horizon 2020 programme VEO (874735) to O.V.; Finnish governmental  
699 subsidy for Health Science Research (TYH 2021315) to Anu.K.; Paulon Säätiö to L.E.C.;  
700 Suomen Lääketieteen Säätiö to L.E.C.; Jane and Aatos Erkko foundation to O.V. The funders  
701 had no role in study design, data collection and analysis, nor decision to publish, or  
702 preparation of the manuscript.

703



704 RNA isolation, library preparations and RNA sequencing was performed at the Institute for  
705 Molecular Medicine Finland FIMM, Genomics unit supported by HiLIFE and Biocenter  
706 Finland. The authors also thank M. Utriainen for expert technical assistance.

707

## References

708

709

1. Wilk AJ, et al. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. *Journal of Experimental Medicine*. 2021;218(8). <https://doi.org/10.1084/jem.20210582>.

710

711

2. Blanco-Melo D, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell*. 2020;181(5):1036-1045.e9.

712

713

3. Hadjadj J, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. *Science*. 2020;369(6504):718–724.

714

715

4. Domizio J Di, et al. The cGAS–STING pathway drives type I IFN immunopathology in COVID-19. *Nature*. 2022;603(7899):145–151.

716

717

5. Barnes BJ, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. *Journal of Experimental Medicine*. 2020;217(6).

718

719

<https://doi.org/10.1084/jem.20200652>.

720

6. Radermecker C, et al. Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. *Journal of Experimental Medicine*. 2020;217(12). <https://doi.org/10.1084/jem.20201012>.

721

722

7. Cabrera LE, et al. Characterization of low-density granulocytes in COVID-19. *PLoS Pathog*. 2021;17(7). <https://doi.org/10.1371/journal.ppat.1009721>.

723

724

8. LaSalle TJ, et al. Longitudinal characterization of circulating neutrophils uncovers phenotypes associated with severity in hospitalized COVID-19 patients. *Cell Rep Med*. 2022;3(10). <https://doi.org/10.1016/j.xcrm.2022.100779>.

725

726

9. Schulte-Schrepping J, et al. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell*. 2020;182(6):1419-1440.e23.

727

728

10. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. *Journal of Experimental Medicine*. 2005;201(11):1771–1780.

729

730

11. Zuo Y, et al. Neutrophil extracellular traps in COVID-19. *JCI Insight*. 2020;5(11). <https://doi.org/10.1172/jci.insight.138999>.

731

732

12. Potere N, et al. Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications. [published online ahead of print: 2022]. <https://doi.org/10.1016/j.xcrm.2022.100779>.

733

734

13. Lechtenberg BC, Mace PD, Riedl SJ. Structural mechanisms in NLR inflammasome signaling [preprint]. *Curr Opin Struct Biol*. 2014;29:17–25.

735

736

14. Aymonnier K, et al. Inflammasome activation in neutrophils of patients with severe COVID-19. *Blood Adv*. 2022;6(7):2001–2013.

737

738

15. Courjon J, et al. Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity. *Blood Adv*. 2021;5(5):1523–1534.

739

740

16. Leal VNC, et al. Severe COVID-19 patients show a dysregulation of the NLRP3 inflammasome in circulating neutrophils. *Scand J Immunol*. [published online ahead of print: 2022]. <https://doi.org/10.1111/sji.13247>.

741

742

17. Sefik E, et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. *Nature*. 2022;606(7914):585–593.

743

744

18. Gawish R, et al. ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF-and IFN $\gamma$ -driven immunopathology. *Elife*. 2022;11. <https://doi.org/10.7554/eLife.74623>.

745

746

19. Rusanen J, et al. A Generic, Scalable, and Rapid Time-Resolved Förster Resonance Energy Transfer-Based Assay for Antigen Detection-SARS-CoV-2 as a

747

748

749

750

751

752

753

754


- 755 Proof of Concept. [published online ahead of print: 2021].  
756 <https://doi.org/10.1128/mBio>.
- 757 20. Kallio MA, et al. Chipster: User-friendly analysis software for microarray and  
758 other high-throughput data. *BMC Genomics*. 2011;12. [https://doi.org/10.1186/1471-](https://doi.org/10.1186/1471-2164-12-507)  
759 [2164-12-507](https://doi.org/10.1186/1471-2164-12-507).
- 760 21. Liu P, et al. ExpressAnalyst: A unified platform for RNA-sequencing analysis in  
761 non-model species. *Nat Commun*. 2023;14(1):2995.
- 762 22. Emig D, et al. AltAnalyze and DomainGraph: Analyzing and visualizing exon  
763 expression data. *Nucleic Acids Res*. 2010;38(SUPPL. 2).  
764 <https://doi.org/10.1093/nar/gkq405>.
- 765 23. Babicki S, et al. Heatmapper: web-enabled heat mapping for all. *Nucleic Acids Res*.  
766 2016;44(1):W147–W153.
- 767 24. Steen CB, et al. Profiling cell type abundance and expression in bulk tissues with  
768 CIBERSORTx. *Methods in Molecular Biology*. Humana Press Inc.; 2020:135–157.
- 769 25. Li Y, et al. Alterations of specific chromatin conformation affect ATRA-induced  
770 leukemia cell differentiation. *Cell Death Dis*. 2018;9(2).  
771 <https://doi.org/10.1038/s41419-017-0173-6>.
- 772 26. CZ CELLxGENE Discover. Chan Zuckerberg Initiative [Internet].  
773 <https://cellxgene.cziscience.com/>.
- 774 27. Corman VM, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time  
775 RT-PCR. *Eurosurveillance*. 2020;25(3). [https://doi.org/10.2807/1560-](https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045)  
776 [7917.ES.2020.25.3.2000045](https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045).
- 777 28. Dagotto G, et al. Comparison of Subgenomic and Total RNA in SARS-CoV-2-  
778 Challenged Rhesus Macaques. [published online ahead of print: 2021].  
779 <https://doi.org/10.1128/JVI>.
- 780 29. Kant R, et al. Common laboratory mice are susceptible to infection with the SARS-  
781 CoV-2 beta variant. *Viruses*. 2021;13(11). <https://doi.org/10.3390/v13112263>.
- 782 30. Schmid AS, et al. Antibody-based targeted delivery of interleukin-4 synergizes  
783 with dexamethasone for the reduction of inflammation in arthritis. *Rheumatology*  
784 (*United Kingdom*). 2018;57(4):748–755.
- 785 31. Seehusen F, et al. Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in  
786 the K18-hACE2 Mouse. *Viruses*. 2022;14(5). <https://doi.org/10.3390/v14051020>.
- 787 32. Rosales C. Neutrophil: A cell with many roles in inflammation or several cell  
788 types? [preprint]. *Front Physiol*. 2018;9(FEB).  
789 <https://doi.org/10.3389/fphys.2018.00113>.
- 790 33. Walle L Vande, Lamkanfi M. Inflammasomes: Caspase-1-activating platforms  
791 with critical roles in host defense. *Front Microbiol*. 2011;2(JAN).  
792 <https://doi.org/10.3389/fmicb.2011.00003>.
- 793 34. Perregaux D, Gabel CA. Interleukin-1 $\beta$  maturation and release in response to ATP  
794 and nigericin. Evidence that potassium depletion mediated by these agents is a  
795 necessary and common feature of their activity. *Journal of Biological Chemistry*.  
796 1994;269(21):15195–15203.
- 797 35. Gong YN, et al. Chemical probing reveals insights into the signaling mechanism of  
798 inflammasome activation. *Cell Res*. 2010;20(12):1289–1305.
- 799 36. Silvin A, et al. Elevated Calprotectin and Abnormal Myeloid Cell Subsets  
800 Discriminate Severe from Mild COVID-19. *Cell*. 2020;182(6):1401–1418.e18.
- 801 37. Simard JC, et al. S100A8 and S100A9 induce cytokine expression and regulate the  
802 NLRP3 inflammasome via ROS-dependent activation of NF- $\kappa$ B(1.). *PLoS One*.  
803 2013;8(8). <https://doi.org/10.1371/journal.pone.0072138>.

- 804 38. Jacob C, et al. DMSO-treated HL60 cells: a model of neutrophil-like cells mainly  
805 expressing PDE4B subtype. *Int Immunopharmacol.* 2002;2(12):1647–1656.
- 806 39. Tang Y, et al. Excessive IL-10 and IL-18 trigger hemophagocytic  
807 lymphohistiocytosis–like hyperinflammation and enhanced myelopoiesis. *Journal of*  
808 *Allergy and Clinical Immunology.* 2022;150(5):1154–1167.
- 809 40. Xue Y, et al. Cardiopulmonary Injury in the Syrian Hamster Model of COVID-19.  
810 *Viruses.* 2022;14(7). <https://doi.org/10.3390/v14071403>.
- 811 41. Vargas F, et al. Intravital imaging of 3 different microvascular beds in SARS-CoV-  
812 2-infected mice. *Blood Adv.* 2023;7(15):4170–4181.
- 813 42. Winkler ES, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes  
814 severe lung inflammation and impaired function. *Nat Immunol.* 2020;21(11):1327–  
815 1335.
- 816 43. Zhang Y, et al. Neutrophil subsets and their differential roles in viral respiratory  
817 diseases [preprint]. *J Leukoc Biol.* 2022;111(6):1159–1173.
- 818 44. Camp J V., Jonsson CB. A role for neutrophils in viral respiratory disease  
819 [preprint]. *Front Immunol.* 2017;8(MAY). <https://doi.org/10.3389/fimmu.2017.00550>.
- 820 45. McKenna E, et al. Neutrophils in COVID-19: Not Innocent Bystanders [preprint].  
821 *Front Immunol.* 2022;13. <https://doi.org/10.3389/fimmu.2022.864387>.
- 822 46. Lee JS, et al. Immunophenotyping of covid-19 and influenza highlights the role of  
823 type i interferons in development of severe covid-19. *Sci Immunol.* 2020;5(49).  
824 <https://doi.org/10.1126/sciimmunol.abd1554>.
- 825 47. Sinha S, et al. Dexamethasone modulates immature neutrophils and interferon  
826 programming in severe COVID-19. *Nat Med.* 2022;28(1):201–211.
- 827 48. Takeuchi O, Akira S. Pattern Recognition Receptors and Inflammation [preprint].  
828 *Cell.* 2010;140(6):805–820.
- 829 49. Israelow B, et al. Mouse model of SARS-CoV-2 reveals inflammatory role of type  
830 i interferon signaling. *Journal of Experimental Medicine.* 2020;217(12).  
831 <https://doi.org/10.1084/JEM.20201241>.
- 832 50. Broz P, Dixit VM. Inflammasomes: Mechanism of assembly, regulation and  
833 signalling [preprint]. *Nat Rev Immunol.* 2016;16(7):407–420.
- 834 51. Hoang TN, et al. Modulation of type I interferon responses potently inhibits SARS-  
835 CoV-2 replication and inflammation in rhesus macaques.  
836 <https://doi.org/10.1101/2022.10.21.512606>.
- 837 52. Lucas C, et al. Longitudinal analyses reveal immunological misfiring in severe  
838 COVID-19. *Nature.* 2020;584(7821):463–469.
- 839 53. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus  
840 in Wuhan, China. *The Lancet.* 2020;395(10223):497–506.
- 841 54. Song X, et al. Little to no expression of angiotensin-converting enzyme-2 on most  
842 human peripheral blood immune cells but highly expressed on tissue macrophages.  
843 *Cytometry Part A.* [published online ahead of print: February 1, 2020].  
844 <https://doi.org/10.1002/cyto.a.24285>.
- 845 55. Nikitina E, et al. Monocytes and macrophages as viral targets and reservoirs  
846 [preprint]. *Int J Mol Sci.* 2018;19(9). <https://doi.org/10.3390/ijms19092821>.
- 847 56. Patel AA, Ginhoux F, Yona S. Monocytes, macrophages, dendritic cells and  
848 neutrophils: an update on lifespan kinetics in health and disease [preprint].  
849 *Immunology.* 2021;163(3):250–261.
- 850 57. Zhou J, et al. Opsonization of malaria-infected erythrocytes activates the  
851 inflammasome and enhances inflammatory cytokine secretion by human macrophages.  
852 *Malar J.* 2012;11. <https://doi.org/10.1186/1475-2875-11-343>.

- 853 58. Labzin LI, Lauterbach MAR, Latz E. Interferons and inflammasomes: Cooperation  
854 and counterregulation in disease [preprint]. *Journal of Allergy and Clinical*  
855 *Immunology*. 2016;138(1):37–46.
- 856 59. Pothlichet J, et al. Type I IFN Triggers RIG-I/TLR3/NLRP3-dependent  
857 Inflammasome Activation in Influenza A Virus Infected Cells. *PLoS Pathog*.  
858 2013;9(4). <https://doi.org/10.1371/journal.ppat.1003256>.
- 859 60. Kopitar-Jerala N. The role of interferons in inflammation and inflammasome  
860 activation [preprint]. *Front Immunol*. 2017;8(JUL).  
861 <https://doi.org/10.3389/fimmu.2017.00873>.
- 862 61. Robertson SE, et al. Expression and alternative processing of IL-18 in human  
863 neutrophils. *Eur J Immunol*. 2006;36(3):722–731.
- 864 62. Rubio-Rivas M, et al. WHO Ordinal Scale and Inflammation Risk Categories in  
865 COVID-19. Comparative Study of the Severity Scales. *J Gen Intern Med*.  
866 2022;37(8):1980–1987.
- 867
- 868

869

Figures & figure legends




870  
871  
872  
873  
874  
875


**Figure 1. Comparison of gene expression in granulocyte populations of COVID-19 patients using RNA-seq analysis.** (A) Principal component analysis (PCA) of the RNA-seq samples (n = 7 for HC PMNs, n = 19 for COVID-19 PMNs (n = 11 and 8 for severe and mild, respectively), n = 6 for severe COVID-19 LDGs). (B) Ridgeline diagrams depicting the top 10 enriched signal pathways from the genes differentially expressed by LDGs versus PMNs during severe COVID-19, including an

876 overrepresentation analysis (ORA) using KEGG database and gene-set enrichment analysis (GSEA)  
877 according to Reactome database. Both enrichment analyses were made using ExpressAnalyst and are  
878 sorted by P-value, obtained from Welch's t-test. (C) Heatmap of the top 95 differentially expressed  
879 genes between PMNs from healthy controls, mild and severe COVID-19, as well as LDGs from severe  
880 disease, identified by unsupervised ICGS analysis based on correlation, using AltAnalyze software.  
881

A




B



882


883 **Figure 2. Increased IFN-I related gene expression in mature COVID-19 neutrophils.** (A)  
 884 Deconvoluted RNA-seq data. The cellular composition in isolated PMN and LDG fractions was  
 885 estimated using CIBERSORTx through the identification of cell populations based on RNA-seq. The  
 886 bar plots in the figure represent the cell composition of each RNA-seq sample, offering insights on  
 887 sample purity. (B) Heatmap of differentially expressed IFN-related genes in COVID-19 PMNs and  
 888 LDGs as compared to HC PMNs. RNA sequencing was performed on purified PMNs from healthy  
 889 controls, mild COVID-19 and severe COVID-19, as well as severe COVID-19 LDGs. The heatmap  
 890 was reduced to include only the samples with the highest purity for their cell type, determined by a  
 891 cell fraction over 0.8 of mature or immature neutrophils for PMNs and LDGs, respectively, as  
 892 identified by CIBERSORTx. The heatmap was clustered by complete linkage and ordered by Spearman's  
 893 rank. n = 13 COVID-19 PMNs (7 severe, 6 mild), n = 4 severe COVID-19 LDGs and n = 5 HC PMNs.





**Figure 3. Inflammasome related gene expression and cytokine secretion in PMNs during severe COVID-19.** (A-B) Ridgeline diagrams of overrepresentation analyses (ORA) according to Reactome and KEGG databases, depicting the top 10 enriched signaling pathways in PMNs during severe COVID-19 compared to (A) healthy controls and (B) mild COVID-19. (C) IL-1 $\beta$  and (D) IL-18 levels in 24-h cell culture supernatants from COVID-19 (n = 11 for IL-1 $\beta$  and 9 for IL-18) and HC PMNs (n = 6 for both). (E) IL-1 $\beta$  and (F) IL-18 levels in 24-h cell culture supernatant from PMNs exposed or non-exposed to purified SARS-CoV-2 viral particles (10 virus particles / PMN) (n = 3). (G) Caspase1 activity in PMNs following a 2-h stimulation with nigericin or purified SARS-CoV-2 viral particles (10 virus particles / PMN). For HC PMNs, n = 9 for mock and nigericin and n = 6 for SARS-CoV-2 exposure. For COVID-19 PMNs, n = 12 for mock and nigericin and n = 9 for SARS-CoV-2 exposure. \*p < 0.05 and \*\*p < 0.01. Data presented as mean  $\pm$  SD. Tukey's multiple comparisons test for mixed-effect analysis was applied for (G), meanwhile P values for (C-F) were calculated with the Mann-Whitney U-test.


894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908



909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920


**Figure 4. Comparative neutrophil transcriptomics of COVID-19 and non-COVID-19 patients.**

Bar graphs represent the activation levels of selected pathways and processes as identified by neutrophil transcriptomics. The analysis includes IFN- $\alpha$  responses, IL-1 $\beta$  production, TLR signaling, NLRP3 inflammasomes, and pyroptosis as determined through the Gene Ontology (GO) database. The NOD-like receptor signaling pathway was investigated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, and the inflammasome pathway was explored via the REACTOME database. The graphs compare the activation levels of these pathways in healthy controls (HC), non-COVID patients with similar symptoms (COVID-19 negative), and COVID-19 positive individuals. Statistical significance is denoted as follows: \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ . P values were calculated with Kruskal-Wallis test.




**Figure 5. IFN-I primes inflammasome activation while COVID-19 PMNs show defective inflammasome responses *ex vivo*.** Isolated HC or COVID-19 PMNs were non-stimulated or stimulated 4h with IFN-I (combination of  $2.7 \times 10^4$  IU/ml IFN- $\alpha$  and IFN- $\beta$ ) or 20 ng/ml LPS (1<sup>st</sup> signal), followed by 4h with 2.5  $\mu$ M nigericin or purified SARS-CoV-2 (10:1 virus/PMNs) (2<sup>nd</sup> signal). Then, (A) western blot of pro-IL-1 $\beta$  (31 kD) and active IL-1 $\beta$  (17 kD) was performed from HC PMNs supernatant and cell lysates, (B) IL-1 $\beta$  (n = 5 HC PMN and 9 COVID-19 PMN) and (C) MPO (n = 5 HC PMN and 9 COVID-19 PMN) were measured from supernatants by ELISA. (D-E) Effect of inflammasome inhibitor MCC950 (2  $\mu$ g/ml, added simultaneously with nigericin) on IL-1 $\beta$  secretion in HC (D) and severe COVID-19 PMN (E) supernatant (n = 3). (F) LDH and (G) IL-8 in HC and severe COVID-19 PMN supernatants (n = 3). (H-K) RT-qPCR of selected mRNAs in IFN-I or LPS-primed HC and COVID-19 PMNs (n = 6-8 HC PMN and 7-10 COVID-19 PMN). \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001; n = 2-4. Data were presented as mean  $\pm$  SD. P values calculated with Kruskal-Wallis test for the comparison between treatments by group (HC or COVID-19 PMNs), and Mann-Whitney test for the comparison between HC and COVID-19 PMNs by individual treatment for (B-G), and Two-way ANOVA Tukey's multiple comparisons test for (B, H-K). Data presented as mean  $\pm$  SD.

921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936



937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947

**Figure 6. Correlation analysis between clinical parameters and *ex vivo* PMN inflammasome activation.** (A) Spearman's correlation matrix depicting the relationships among clinical parameters and results of *ex vivo* experimentation. For the WHO ordinal scale, the baseline parameters were used. (B-C) Linear regression analysis demonstrating the associations between: (B) Positive association between PMN Caspase1 activity, measured after *ex vivo* nigericin stimulation, and the levels of Calprotectin in the matched patient's peripheral blood; (C) Negative association between *ex vivo* stimulated PMN IL-1 $\beta$  levels (LPS+Nig) and the blood neutrophil count in matched patients at the time of sampling (n=12). LOS = length of stay. WHO = World Health Organization. Min = minimum. Casp1 = caspase1. LPS or IFN + nig = lipopolysaccharide or type I interferon + nigericin *ex vivo* stimulation.



**Figure 7. Immature neutrophils express IL-18 in response to inflammasome activation.**

(A) Heatmap depicting selected differentially expressed inflammasome related genes from RNA sequencing performed in PMNs from HC, mild and severe COVID-19, as well as severe COVID-19 LDGs. Only the samples with the highest purity, determined by a cell fraction over 0.8 of mature or immature neutrophils for PMN and LDG, respectively, (identified by CIBERSORTx) are included. The heatmap was clustered by complete linkage and ordered by Spearman's rank.

(B) UMAP analysis of the COVID-19 Immune Atlas, which integrates 5 public COVID-19 PBMC single-cell transcriptomics datasets, created using CELLxGENE. (Top) UMAP showing the clustering of CD16<sup>+</sup> cells (mature, FCGR3B expressing cells) and CD66b<sup>+</sup> cells (immature, CEACAM8 expressing cells). Each dot represents a single cell colored according to the expression level of a selected gene. The color scale ranges from green (low expression) to purple (high expression). (Bottom) Pie chart summarizing the percentage of mature (black) and immature (blue) cells in the dataset.


(C) The fraction of mature and immature neutrophils cells expressing inflammasome related genes identified in Figure 7B are shown in a bar graph. For each gene, the proportion of expressing cells is shown in light blue, while the proportion of negative or not-expressing cells is shown in gray. Zoomed-in bar graph depicts the proportion of mature and immature cells expressing each gene.

(D-G) Isolated COVID-19 LDGs or HL-60 cells (differentiated for 5 days with 1% DMSO) were non-stimulated or stimulated 4h with IFN-I or LPS (1<sup>st</sup> signal), followed by 4h with nigericin (2<sup>nd</sup> signal) in the presence or absence of inflammasome inhibitors MCC950 or YVAD as previously. Secretion of (D, F) IL-1 $\beta$  and (E, G) IL-18 were measured from the supernatants by ELISA (n = 2 for LDGs and 3-5 for HL-60).

\*p < 0.05 and \*\*p < 0.01. P values calculated with Kruskal-Wallis test. Data presented as mean  $\pm$  SD.

(H) Volcano plot of differentiated vs undifferentiated HL-60 cells gene expression from GSE93996, with inflammasome related genes marked in blue. Only significant DE genes are shown (adjusted p value < 0.05).

948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973



**Figure 8. Neutrophil accumulation in the lungs correlates with viral loads in SARS-CoV-2 infected mice.** Female BALB/c mice were intranasally inoculated with  $5 \times 10^5$  TCID50 SARS-CoV-2 MaVie strain or PBS as control and euthanized at 2 dpi or 4 dpi.

(A) RNA was isolated from lungs and subjected to RT-qPCR targeting viral subE and GAPDH as housekeeping gene. The relative expression of subE was measured using the comparative Ct method as compared to mock-infected control (in which subE was undetectable but set to 40 Ct) \*\*\*\*  $p < 0.0001$ . P values calculated with Welch's t-test.

(B) Quantification based on morphometric analysis that determines the area of immunolabelling for SARS-CoV-2 nucleoprotein in relation to total tissue area. \*\*\* $p < 0.001$ . P values calculated with Welch's t-test.

(C) Quantification of Ly-6G based on morphometric analysis that determines the area of immunolabelling for Ly6G in relation to total tissue area in mock-infected controls. \*\*\*\* $p < 0.0001$ . P values calculated with ordinary one-way ANOVA using Tukey's multiple comparisons test. Black line represents the mean.


(D) Left column: immunohistochemistry for SARS-CoV-2 nucleoprotein; right column: immunohistochemistry for Ly6G (neutrophil marker), hematoxylin counterstain. Bars = 500  $\mu$ m (large images) and 50  $\mu$ m (insets).

At 2 dpi (top), the arrow points at a bronchus with viral antigen expression in epithelial cells. A close-up of the bronchus (bottom; B: bronchial lumen) shows degenerated and slough off antigen positive epithelial cells. Adjacent alveoli exhibit viral antigen expression in typeI (arrowhead) and typeII (arrow) pneumocytes. The overview (top) shows neutrophils between the infected bronchial (arrow) epithelial cells, in parenchymal areas (arrowhead; right inset) and in capillaries (arrowheads). A close-up of the bronchus (bottom; B: bronchial lumen) highlights numerous neutrophils between degenerate (arrowheads) epithelial cells.

At 4 dpi (middle), there are focal areas with antigen expression in alveolar epithelial cells and infiltrating macrophages. Neutrophils are present among the infiltrating cells (arrow) as individual cells (inset: arrows) or in aggregates (inset: arrowhead).

974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001

1002 The bottom shows the lung of a mock-infected control animal. There is no viral antigen expression.  
1003 Staining for Ly6G depicts individual neutrophils in larger vessels (inset: arrow) or in capillaries (inset:  
1004 arrowheads).



**Figure 9. Neutrophils of SARS-CoV-2 infected mice display increased caspase1 activation ability that is dependent on IFN-I.**

Female BALB/c mice were intranasally inoculated with  $5 \times 10^5$  TCID50 SARS-CoV-2 MaVie strain or PBS as control. Lungs were harvested at 2 and 4 dpi and Ly-6G+ neutrophils isolated based on positive selection with magnetic beads. RNA was isolated and subjected to transcriptomic analysis by RNA-seq. (A) Principal component analysis (PCA) of the PBS-inoculated control and SARS-CoV-2 infected mice lung neutrophil RNA-seq samples. (B) Heatmap of the top DEGs. (C) Volcano plots of DEGs between neutrophils isolated from SARS-CoV-2 infected mice versus uninfected PBS-inoculated mice. Blue points represent significant terms (adjusted p-value < 0.05), while smaller gray points represent non-significant terms. Relevant inflammasome and interferon related genes are shown with larger and darker blue points.


1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016



1017 (D) Caspase1 activity in isolated mice neutrophils following a 2-h stimulation with nigericin was  
1018 assessed by a bioluminescence method (Caspase-Glo® 1 Inflammasome Assay).  
1019 (E-G Mice were intraperitoneally inoculated with 250 µg anti-IFNAR or IgG1 isotype control directly  
1020 after infection with SARS-CoV-2 and lung neutrophils isolated at 2 dpi (including also intranasally  
1021 PBS-inoculated control mice without intraperitoneal injection).  
1022 (E) Caspase1 activity was assessed following a 2-h stimulation with nigericin by bioluminescence  
1023 method.  
1024 (F-G) RNA was isolated from isolated neutrophils and fold change mRNA expressions of (C) Caspase1  
1025 (Casp1) and (D) IL-1β (IL1b) in isotype control and anti-IFNAR treated infected mice as compared to  
1026 mock-infected control mice assessed by RT-qPCR.  
1027 DEG = differentially expressed genes.  
1028 \*p < 0.05, and \*\*p < 0.01. P values for D, E and H panels were calculated with ordinary one-way  
1029 ANOVA using Tukey's multiple comparisons. Welch's t-test was used for panels F and G. Data  
1030 presented as mean ± SD.

1031

## Supplementary figure legends



1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052


### Supplementary Figure 1. Enriched pathways and differentially expressed genes in severe COVID-19 PMNs and LDGs.

(A-B) Volcano plots of enriched gene sets in severe COVID-19 PMNs versus (A) HC PMNs and (B) severe COVID-19 LDGs, using KEGG database. Each point represents a single gene set, where the x-axis measures its odds ratio, while the y-axis shows its  $-\log(p\text{-value})$ . Blue points represent significant terms (adjusted  $p\text{-value} < 0.05$ ), where darker points represent more significant terms, while smaller gray points represent non-significant terms.

(C-D) Volcano plots of DEGs between severe COVID-19 PMNs versus (C) HC PMNs and (D) severe COVID-19 LDGs. Blue points represent significant terms (adjusted  $p\text{-value} < 0.05$ ), while smaller gray points represent non-significant terms. Relevant inflammasome related or -predicted genes based on the literature, according to GENESHOT (34), are shown with a larger and darker blue point.


(E-F) Pie charts of interferon and inflammasome related genes, according to GENESHOT from the identified DEGs in severe COVID-19 PMNs, compared to (E) HC PMNs and (F) severe COVID-19 LDGs.

(G-H) Volcano plots of (G) severe COVID-19 PMNs versus mild COVID-19 PMNs and (H) mild COVID-19 PMNs vs HC PMN. Blue points represent significant terms (adjusted  $p\text{-value} < 0.05$ ), while smaller gray points represent non-significant terms. Relevant inflammasome related or predicted genes based on the literature, according to GENESHOT, are shown with a larger and darker blue point. DEG = differentially expressed genes.



**Supplementary Figure 2. Differential expression of interferon and inflammasome related genes in PMNs during COVID-19.** RNA was extracted from isolated HC PMNs (n = 8-13) versus severe COVID-19 PMNs (n = 29-32) and subjected to comparative RT-qPCR using specific primers for OAS1, OAS2, IFIT1, IFI16, caspase1, caspase5, IL1B, NLRP4, NLRC5, NLRP3 and NAIP. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 and \*\*\*\*p < 0.0001. P values calculated with Mann-Whitney U-test. Data presented as mean ± SD.

1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061



**Supplementary Figure 3. Ex vivo stimulation of isolated PMNs.**


(A) IL-18 (n = 2-3 HC PMN and 3 COVID-19 PMN) was measured from supernatants by ELISA following LPS or IFN-I priming (4-h) and subsequent nigericin activation (4-h).

(B-C) Effect of different inflammasome specific inhibitors in cytokine secretion. (A) Effect of inflammasome inhibitor MCC950 (2  $\mu$ g/ml) and YVAD (20  $\mu$ g/ml) on LPS or IFN-I primed (4-h) and nigericin activated (4-h) IL-1 $\beta$  secretion in the supernatant of healthy control PMNs (n = 8). (B-C) Effect of inflammasome inhibitor MCC950 (2  $\mu$ g/ml, added simultaneously with nigericin) on LPS or IFN-I primed (4-h) and nigericin activated (20-h) (B) IL-1 $\beta$  and (C) IL-18 secretion in the supernatant of healthy control PMN (n = 3).

(D) Gene expressions in HC and COVID-19 PMNs after LPS or IFN-I stimulation. A comparison of gene expression in isolated healthy control PMNs versus COVID-19 PMNs after *ex vivo* stimulation with LPS or IFN-I. Extracted RNA was subjected to comparative RT-qPCR using specific primers for NLRP3, NLRC4, NAIP and CASP5 (n = 4-8 for HC PMN and 6-9 for COVID-19 PMN). \*p < 0.05. Two-way ANOVA with Tukey's multiple comparison test was applied. Data were presented as mean  $\pm$  SD.


\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001. P values calculated with Kruskal-Wallis test. Data presented as mean  $\pm$  SD. IFN = interferon type I, LPS = lipopolysaccharide, Nig = nigericin, YVAD = tetrapeptide caspase I inhibitor Tyr-Val-Ala-Asp.

1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080



1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088

**Supplementary Figure 4. Expression of inflammasome related genes in mature and immature neutrophils from COVID-19 PBMCs.** The fraction of mature and immature neutrophils cells expressing 17 inflammasome related genes identified in Figure 7B (shown in black and blue, respectively) are shown in a bar graph. For each gene, the proportion of expressing cells is shown in light blue, while the proportion of negative or not-expressing cells is shown in gray. Zoomed-in bar graph depicts the proportion of mature and immature cells expressing each gene.



**Supplementary Figure 5. Dynamics of animal weight and impact of  $\alpha$ -IFNAR treatment in SARS-CoV-2 infected mice.** Female BALB/c mice were intranasally inoculated with  $5 \times 10^5$  TCID<sub>50</sub> SARS-CoV-2 MaVie strain or PBS as control.

(A) Daily tracking of animal weight performed throughout the experiment (n = 8 for SARS-CoV-2 infected animals, n = 2 for PBS-inoculated animals). The weights of the mice euthanized at 2 dpi (n = 26) did not show significant differences and are not reported.

(B-C) Mice were intraperitoneally inoculated with 250  $\mu$ g anti-IFNAR or IgG1 isotype control directly after infection with SARS-CoV-2 and lung neutrophils isolated at 2 dpi (including also intranasally PBS-inoculated control mice without intraperitoneal injection)

1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098

1099 (B) RNA was isolated from mouse lungs and subjected to RT-qPCR targeting the replication-  
1100 intermediate subgenomic E gene and GAPDH as housekeeping gene. RNA levels were assessed based  
1101 on cycle threshold Ct levels. The expression levels of the target gene SubE were measured and  
1102 normalized to GAPDH levels using the comparative Ct method ( $\Delta\Delta Ct$ ). The fold change values were  
1103 calculated by the formula  $2^{(-\Delta\Delta Ct)}$ , representing the relative gene expression compared to the PBS  
1104 mock-infected control (in which subE was undetectable but set to 40 Ct). No significant differences are  
1105 seen between the two groups.

1106 (C) Histological features, viral antigen expression and extent of neutrophil influx and damage in the  
1107 lung of SARS-CoV-2 infected BALB/C mice after isotype control and anti-IFNAR treatment at 2dpi.  
1108 Left column: Control isotype treated mice; right column: anti-IFNAR treated mice. HE stain (top layer)  
1109 and immunohistology, hematoxylin counterstain (all other images). Bars: 250  $\mu m$  (overview images)  
1110 and 25  $\mu m$  (insets).

1111 In control isotype treated mice, the lung exhibits degeneration and loss of bronchial and bronchiolar  
1112 epithelial cells (HE stain: arrowhead; right inset), with mild inflammatory infiltration. The parenchyma  
1113 exhibits focal areas of increased cellularity, with typeII pneumocyte activation and occasional  
1114 degenerate alveolar epithelial cells (arrows; left inset: degenerate cells (arrowhead) and infiltrating  
1115 neutrophil (arrow)). Staining for SARS-CoV-2 NP confirms epithelial cell infection in bronchus  
1116 (arrowhead; right inset) and alveoli (arrow; left inset). Right inset: Viral antigen expression is seen in  
1117 intact and sloughed off, degenerate epithelial cells. Left inset: Viral antigen expression is seen in both  
1118 typeI (small arrowhead) and typeII (small arrow) pneumocytes; there are also degenerate positive cells  
1119 (large arrowhead). Neutrophils (Ly6G+) are located within focal parenchymal areas of increased  
1120 cellularity (arrows; left inset: arrowheads) and present between degenerate bronchial epithelial cells  
1121 (arrowhead; right inset: arrowhead). Staining for histone H3 shows neutrophil degeneration/NETosis in  
1122 parenchymal areas (arrow; left inset: arrowheads) and associated with degenerate epithelial cells  
1123 (arrowhead; right inset: positive reaction between sloughed off epithelial cells (arrow) and between the  
1124 intact epithelial layer (arrowhead)).

1125 In anti-IFNAR treated animals, the lung exhibits degeneration and loss of bronchial and bronchiolar  
1126 epithelial cells (arrowhead; right inset: arrows), with mild inflammatory infiltration and individual  
1127 neutrophils between intact and sloughed off degenerate epithelial cells (right inset: arrowheads). The  
1128 parenchyma exhibits focal areas of increased cellularity, with typeII pneumocyte activation and  
1129 occasional degenerate alveolar epithelial cells (arrows; left inset: degenerate cells (arrow) and  
1130 infiltrating neutrophils (arrowhead)). Staining for SARS-CoV-2 NP shows epithelial cell infection in  
1131 bronchioles (arrowhead; right inset) and alveoli (arrow; left inset). Right inset: Viral antigen expression  
1132 is seen in intact and sloughed off, degenerate epithelial cells. Left inset: Viral antigen expression is seen  
1133 in pneumocytes (arrow) and infiltrating macrophages (arrowheads). Neutrophils (Ly6G+) locate within  
1134 focal parenchymal areas of increased cellularity (arrows; left inset) and are present between intact (inset:  
1135 arrowhead) and degenerate epithelial cells (arrowhead; right inset: arrow). Staining for histone H3  
1136 shows neutrophil degeneration/NETosis in parenchymal areas (arrow; left inset) and associated with  
1137 degenerate epithelial cells (arrowhead; right inset: positive reaction between sloughed off epithelial cells  
1138 (arrow) and between the intact epithelial layer (arrowhead)).

1139 *Dpi* =            *days*            *post*            *infection*;            *NP*            =            *nucleoprotein*.

1140  
1141  
1142  
1143

## Tables & table legends

**Table 1. Clinical parameters of hospitalized patients (n=34).**

Parameter	Range (Mean $\pm$ SD) or ratio
Age (years)	22 - 80 (58.41 $\pm$ 13.63)
Gender (male:female)	23:11
Hospitalization (days)	3 - 38 (12 $\pm$ 8.63)
WHO Ordinal scale for Clinical improvement: Baseline	1 - 6 (4 $\pm$ 1.07)
WHO Ordinal scale for Clinical improvement: Worst	2 - 8 (4 $\pm$ 1.42)
Deaths (count/total)	1/34
ICU (count/total)	9/34
Corticosteroid use (count/total)	13/34
Length of stay in ICU (days)	1 - 27 (7.38 $\pm$ 9.49)
Max CRP (mg/L)	6 - 466 (159.56 $\pm$ 104.06)
Min lymphocyte count ( $E^9/L$ )	0.08 - 2.02 (0.79 $\pm$ 0.42)
Max neutrophil count ( $E^9/L$ )	1.08 - 29.86 (7.85 $\pm$ 5.73)
Sampling day neutrophil count ( $E^9/L$ )	0.64 - 20.52 (5.65 $\pm$ 3.95)

1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156

The World Health Organization (WHO) Ordinal Scale for clinical improvement is a tool designed specifically to assess and measure the progression and clinical improvement of patients (62). COVID-19 scoring: 1= no limitations of activity, 2= limitations of activity, 3= no oxygen therapy, 4= oxygen by mask or nasal cannulae, 5= non-invasive ventilation or high-flow oxygen, 6= invasive mechanical ventilation without other organ support, 7= invasive mechanical ventilation with other organ support, 8= dead. The baseline score represents the timepoint of the first laboratory sample taken, serving as a reference point for measuring improvement and establishing a starting point for comparison. In contrast, the worst score represents the most severe or critical state of the disease. None of the patients whose samples were used for RNA-seq underwent corticosteroid treatment. *Abbreviations: WHO= World Health Association. ICU = Intensive Care Unit. CRP = C reactive protein. Min = minimum. Max = maximum.*



1157  
1158

**Supplementary Table S1. qPCR primer sequences: gene-specific forward and reverse primers.**

Gene	Forward primer	Reverse primer
AIM2	GGCCAGCAGGAA TCTATCAG	GAAGGGCTTCTTTGCTTTCAGTAC
NAIP	AAGGGATTGTGACATAACGGG	CAGCCGTAGTTCTTCGTAAGC
NLRC5	ACAGCATCCTTAGACACTCCG	CCTTCCCCAAAAGCACGGT
IL1B	CACATGGGATAACGAGGCTT	TCCAGCTGTAGAGTGGGCTT
CASP1	GCTTTCTGCTCTTCCACACC	TCCTCCACATCACAGGAACA
CASP4	CAAGAGAAGCAACGTATGGCA	AGGCAGATGGTCAAACCTCTGTA
CASP5	TTCAACACCACATAACGTGTCC	GTCAAGGTTGCTCGTTCTATGG
IFI16	TCCTCAGATGCCTCCATCAAC	CAGGTTCACTTTCAGTCTTGGT
IFIT5	TAAAAAAGGCCTTGGAGGTG	CCAGGTCTGTGTAGGCAAAT
IRF7	GCTGGACGTGACCATCATGTA	GGGCCGTATAGGAACGTGC
IFIT1	GCGCTGGGTATGCGATCTC	CAGCCTGCCTTAGGGGAAG
IFI6	GGTCTGCGATCCTGAATGGG	TCACTATCGAGATACTTGTGGGT
OAS1	TGTCCAAGGTGGTAAAGGGTG	CCGGCGATTAACTGATCCTG
OAS2	CTCAGAAGCTGGGTTGGTTTAT	ACCATCTCGTCGATCAGTGTC
GAPDH	TTGGCTACAGCAACAGGGTG	GGGGAGATTCAGTGTGGTGG

1159  
1160

1161  
1162  
1163

**Supplementary Table S2. Histological changes as well as SARS-CoV-2 nucleoprotein and RNA expression in female BALB/C mice infected with SARS-CoV-2.**

**A. Experiment 1.** Infected animals were euthanized and examined at 2 and 4 days post infection.

Infection, dpi [Animal no]	Histological changes, viral antigen and Ly6G expression <sup>1</sup> in lungs	Viral subE (and GAPDH) RNA Cts <sup>2</sup>
<b>5 x 10<sup>5</sup> PFU, 2 dpi</b> [1.1.1]	<b>HE:</b> bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries; NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC	15.12 (13.47)
<b>5 x 10<sup>5</sup> PFU, 2 dpi</b> [1.1.2]	<b>HE:</b> bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC	15.92 (13.79)
<b>5 x 10<sup>5</sup> PFU, 2 dpi</b> [1.1.3]	<b>HE:</b> bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen) and in association with degen BEC	15.56 (13.83)
<b>5 x 10<sup>5</sup> PFU, 2 dpi</b> [1.1.4]	<b>HE:</b> bronchioles with abundant degen EC (in place and sloughed off); parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchus/bronchioles (almost all BEC, some also degen); most alveoli with pos AEC <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli (partly degen)	16.33 (14.81)
<b>5 x 10<sup>5</sup> PFU, 4 dpi</b> [1.2.1]	<b>HE:</b> one bronchiole with degen EC (in place and sloughed off), others unaltered; large parenchymal area with extensive type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) <b>vAg:</b> some bronchioles with extensive expression (almost all BEC, some also degen), others with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected areas) <b>Ly6G:</b> some increase in NL in lumen of vessels and capillaries, NL in lumen of bronchioles and alveoli in affected area (partly degen)	31.68 (11.64)
<b>5 x 10<sup>5</sup> PFU, 4 dpi</b> [1.2.2]	<b>HE:</b> bronchioles with a few degen EC (in place or sloughed off), others unaltered; small parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) <b>vAg:</b> some bronchioles with several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) <b>Ly6G:</b> some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen)	31.86 (11.78)
<b>5 x 10<sup>5</sup> PFU, 4 dpi</b> [1.2.3]	<b>HE:</b> bronchioles with a few degen EC (in place or sloughed off), others unaltered; small parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) <b>vAg:</b> some bronchioles with several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) <b>Ly6G:</b> some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen)	31.33 (11.71)
<b>5 x 10<sup>5</sup> PFU, 4 dpi</b> [1.2.4]	<b>HE:</b> bronchioles with rare degen EC, most unaltered; parenchymal area with type II pn activation, degen AEC and increased cellularity (leukocytes incl NL) <b>vAg:</b> some bronchioles with a few to several (partly degen) pos BEC, most with a few individual or no pos BEC; patches of alveoli with pos AEC (within and outside affected area) <b>Ly6G:</b> some increase in NL in lumen of vessels and capillaries, a few NL in lumen of bronchioles and alveoli in affected area (partly degen)	35.02 (11.89)
<b>PBS (control), 2 dpi</b> [1.3.1]	<b>Lung:</b> NHA <b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	n.d., set to 40 (13.65)
<b>PBS (control), 2 dpi</b> [1.3.2]	<b>Lung:</b> NHA <b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	n.d., set to 40 (15.66)
<b>PBS (control), 2 dpi</b>	<b>Lung:</b> NHA	n.d., set to 40

[1.3.3]	<b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	(14.32)
<b>PBS (control), 2 dpi</b> [1.3.4]	<b>Lung:</b> NHA <b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	n.d., set to 40 (14.57)

1164

1165

1166

**B. Experiment 3.** Infected animals were treated with control isotype or IFNAR blocking antibody prior to euthanization and examination at 2 days post infection.

Infection, treatment [Animal no, sex, age]	Histological changes, viral antigen (vAg), Ly6G and histone H3 expression <sup>1</sup> in lungs	Viral subE (and GAPDH) RNA Cts <sup>2</sup>
<b>5 x 10<sup>5</sup> PFU, control isotype</b> [3.1.1]	<b>HE:</b> bronchus and connected bronchiole with abundant degen EC (in place or sloughed off); endothelial cell activation in adjacent muscular veins, with some leukocyte adhesion; adjacent parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchus/bronchioles (almost all BEC, also degen), and large adjacent areas of alveoli with pos AEC <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) <b>H3:</b> pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli)	14.75 (12.63)
<b>5 x 10<sup>5</sup> PFU, control isotype</b> [3.1.2]	<b>HE:</b> some bronchioles with abundant degen EC (in place or sloughed off); endothelial cell activation in some adjacent vessels; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in some bronchioles (almost all BEC, also degen), large (adjacent) areas of alveoli with pos AEC <b>Ly6G:</b> mild increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) <b>H3:</b> pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli)	16.61 (11.54)
<b>5 x 10<sup>5</sup> PFU, control isotype</b> [3.1.3]	<b>HE:</b> bronchioles with abundant degen EC (in place or sloughed off); endothelial cell activation in some muscular veins, with leukocyte rolling and subendothelial infiltration (vasculitis), other vessels packed with leukocytes; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchioles (patches of BEC to almost all BEC, also degen), large (adjacent) areas of alveoli with pos AEC <b>Ly6G:</b> mild increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (often degen) <b>H3:</b> extensive pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli)	16.00 (12.71)
<b>5 x 10<sup>5</sup> PFU, control isotype</b> [3.1.4]	<b>HE:</b> bronchus and bronchioles with abundant degen EC (in place or sloughed off); endothelial cell activation in some muscular veins, with leukocyte rolling and pv infiltration; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchioles (patches to almost all BEC, also degenerate), large (adjacent) areas of alveoli with pos AEC <b>Ly6G:</b> mild increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degenerate) <b>H3:</b> pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli); most extensive in alveoli	15.07 (13.83)
<b>5 x 10<sup>5</sup> PFU, anti-IFNAR</b> [3.2.1]	<b>HE:</b> bronchus and connected bronchiole with abundant degen EC (in place or sloughed off); endothelial cell activation in muscular veins, with some leukocyte adhesion; patchy parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchioles (abundant to almost all BEC, also degen), and large areas of alveoli with pos AEC <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) <b>H3:</b> pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli)	13.98 (12.44)
<b>5 x 10<sup>5</sup> PFU, anti-IFNAR</b> [3.2.2]	<b>HE:</b> bronchioles with occ degen EC (in place or sloughed off); endothelial cell activation in muscular veins, with some leukocyte adhesion; parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> extensive expression in bronchus/bronchioles (almost all BEC, also degen), and large areas of alveoli with pos AEC <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) <b>H3:</b> pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli)	14.90 (13.12)
<b>5 x 10<sup>5</sup> PFU, anti-IFNAR</b>	<b>HE:</b> infected bronchus with a few degen EC (in place); mild endothelial cell activation in some adjacent vessels; (adjacent) parenchymal areas with type II	28.79 (14.09)

[3.2.3]	pn activation and increased cellularity <b>vAg:</b> a few individual EC in bronchus and some bronchioles, one with all EC pos, adjacent large patches of alveoli with pos AEC <b>Ly6G:</b> increase in individual NL in lumen of vessels and capillaries (mainly in affected areas), a few NL in lumen and between EC of infected bronchiole, and in alveoli in affected areas <b>H3:</b> rare pos reaction in alveoli	
<b>5 x 10<sup>5</sup> PFU, anti-IFNAR</b> [3.2.4]	<b>HE:</b> infected bronchioles with variable amount of degen EC (in place or sloughed off); endothelial cell activation in some vessels, with leukocyte rolling and pv infiltration; (adjacent) parenchymal areas with type II pn activation, occ degen AEC and increased cellularity <b>vAg:</b> bronchus and bronchioles with individual, patches of to almost all BEC pos (also degen) and cell free viral Ag in lumen, large (adjacent) areas of alveoli with pos AEC (also degen) <b>Ly6G:</b> increase in NL in lumen of vessels and capillaries in affected areas, NL in lumen of bronchioles and alveoli (partly degen) <b>H3:</b> extensive pos reaction in areas with degen NL (lumen of bronchioles, affected alveoli)	13.54 (13.33)
<b>PBS (control), none</b> [3.3.1]	<b>Lung:</b> NHA <b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	n.d., set to 40 (10.20)
<b>PBS (control), none</b> [3.3.2]	<b>Lung:</b> NHA <b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	n.d., set to 40 (11.04)
<b>PBS (control), none</b> [3.3.3]	<b>Lung:</b> NHA <b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	n.d., set to 40 (14.06)
<b>PBS (control), none</b> [3.3.4]	<b>Lung:</b> NHA <b>vAg:</b> neg <b>Ly6G:</b> a few individual NL in lumen of vessels and capillaries	n.d., set to 40 (13.70)

1167

1168

1169

1170

1171

1172

1173

The age of the infected animals were 9 weeks in experiment 1 and 8 weeks in experiment 3; alv – alveolar; BEC – bronchiolar epithelial cells; degen – degenerate (this also includes apoptotic and/or necrotic); EC – epithelial cells; F – female; HE – histological features assessed in a hematoxylin-eosin stained section; incl – including; M – male; neg – negative; NHA – no histological abnormality; NL – neutrophilic leukocytes (i.e. neutrophils); occ – occasional; pc – pneumocytes; pos – positive; pv – perivascular; vAg – viral antigen; we – weeks; n.d. – not detected

1174

<sup>1</sup> Viral antigen and Ly6G expression determined by immunohistochemistry.

1175

1176


1177

1178



<sup>2</sup> Obtained RT-qPCR cycle threshold values (Cts) for viral subgenomic E gene (subE) as a measure of viral replication and GAPDH mRNA as the housekeeping gene. As expected, for PBS control animals no Ct value for viral subE was obtained. The subE Ct for control animals was set to the detection limit of 40 to facilitate fold change calculations presented in Figure 8A and Supplementary Fig. 5B.

**A**


- COVID-19 LDG
- COVID-19 PMN
- HC PMN



**B**













**C**




**A**

medRxiv preprint doi: <https://doi.org/10.1101/2023.09.07.23285180>; this version posted October 12, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).


**B**

**A****B****C****D****E****F****G**




COVID

- Healthy Controls
- COVID Negative
- COVID Positive




COVID

- Healthy Controls
- COVID Negative
- COVID Positive




COVID

- Healthy Controls
- COVID Negative
- COVID Positive




COVID

- Healthy Controls
- COVID Negative
- COVID Positive




COVID

- Healthy Controls
- COVID Negative
- COVID Positive



COVID












- Healthy Controls
- COVID Negative
- COVID Positive














COVID




- Healthy Controls
- COVID Negative
- COVID Positive






**A****B****C****D****E****F****G****H****I****J****K**

**A****B****C**



**A****B****C****D****E****H****F****G**

**A****B****C****D****SARS-CoV-2 NP****Ly6G**



2 dpi




4 dpi




Control




**A**




**B**




**C**




**D**



**E**



**F**



**G**

